SlideShare ist ein Scribd-Unternehmen logo
1 von 51
Downloaden Sie, um offline zu lesen
BRAND PLAN FOR
2010
BRAND – GLYCOMET (US VITAMIN)
YEAR
2010
PREPARED BY : MITESH SHAH
SUBMITTED TO : Mr. PRATIM VORA
YEAR 2010
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
2
To provide our manager, our peers and our Representatives with a clear and
concise review of the primary strategies, the tactics and the performance objectives that we
have planned for the upcoming year. The reader of our Executive Summary should be able
to answer the following regarding our responsibilities, objectives and measurements for
the year:
Our annual unit sales and revenue objectives for the year.
Our most recent years' performance compared to our projected performance.
The primary strategies and tactics that will get us there.
Our customer segmentation scheme by history and by forecast.
Our rationale for our targeted regions and territories.
An overview of sales of our organization.
Our anticipated requirements for hiring, training and developing sales personnel.
Our measurement criteria.
 This should concisely highlight brnd Plan.
 This must be appealing, compelling and well organized enough for the reader to
obtain a very comprehensive understanding of our entire market and our plan of
attack.
EXECUTIVE SUMMARY
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
3
TABLE OF CONTENT
Sl. No. Particular Page No.
Company – US Vitamin profile 05
 India Operation 05

Therapeutically segments covered in India 05

Business unit 05

Market Standing 06

Marketing capabilities 06

Distribution Network 07
 Partners in India 07

Manufacturing facilities 08

Diabetes 08

Market in world 10
Brand – Glycomet Detail 11
Product Design 12
Price 14
Promotional Strategies 15
 Effective promotional strategy 15
 Pre Launch Activities 15
 Post Launch Activities 16
Situational and Competitive Analysis 17
SWOT Analysis 19
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
4
Anti Diabetic Drugs – Existing Brands 21
 Sales Plan 32

Sales Planning for the sales manager 32

 Sales Objectives 33

 Hiring Plan 42
 Recruiting, Hiring and Training Table 43

Training Requirement 45

Plan our Incentive Package 45

Award Programs 46
Report and Monitor 48
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
5
INDIA OPERATIONS
 USV total sales for the year 2008-09 were Rs. 6050 million.
 USV sales in India contribute to 68% of our total business.
 USV rank 23rd in the Indian Pharmaceutical Industry (Source: ORG; April 2009) with
leadership positions in several product categories.
THERAPEUTIC SEGMENTS COVERED IN INDIA INCLUDE
 Diabetes
 Cardiovascular
 Orthopaedics
 Nutritional
 Respiratory
 Dermatology
 Gynaecology
 Paediatrics
 CNS
BUSINESS UNIT
 The domestic operations are divided into six business units each with
separate infrastructure for sales and marketing.
Condor
 Focus on Diabetes
Corvette
 Focus on Cardiology
Pharma
 Focus on Gynecology,
Dermatology, Respiratory
and Pediatrics
Centra
 Focus on Neurology and
Psychiatrist
Conquer
 Focus on Diabetes and
Cardiology
Cosmeceutical
 Focus on Dermatology and
Cosmetology
COMPANY – USV PROFILE
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
6
Market standing
 Leader in Diabetes & Cardiology in terms of prescription generation.
 Presence in Cosmetology with a leading European brand.
 Presence in Nutritionals, Respiratory, Gynecology through innovative products from
partners in USA and Europe.
 USV lead the oral anti-diabetic segment in India
in terms of value as well as prescriptions. USV have
maintained a leadership position in this segment for
almost two decades.
 32% of our sales are contributed by the anti-
diabetic portfolio, which includes insulin.
 We lead in the cardiovascular disease segment
in terms of prescription generation. In terms of value,
we rank amongst the first 10 companies in India. The
cardiology portfolio contributes 32% to our sales.
 Presence in Respiratory, Nutritionals, Orthopedics and Gynecology segments is attributed
to innovative products through partnerships with companies from Europe and USA.
 We have a significant presence in Dermatology with a leadership position in the anti-acne
segment. We have recently launched Sebamed range of skin-care products from Europe.
 USV has also ventured into the CNS segment with the launch of a new division to cater the
needs of Neurologists and Psychiatrists.
MARKETING CAPABILITIES
 We have a focused marketing team for every business unit. The emphasis is on
brand building:
 Rigorous and regular medical and sales training of the field force
 Enhancing knowledge about our products and related disease among physicians by
organizing Continuing medical education programs
 Enhancing detection of undiagnosed diseases through detection camps
 Enhancing patients' awareness about diseases by organizing several patient
education programs
 Ethical promotion of pharmaceutical products
 Some examples of our Brand Building Capabilities
 We are the 3rd largest by prescription for calcium product
 Our products have leadership positions in anti-oral diabetic, anti-coagulant and
multivitamin (without minerals) markets
 Our focused marketing capabilities and ethical promotion of scientific products
resulted in establishing premium brands
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
7
DISTRIBUTION NETWORK
 A 1300 strong sales team works to provide essential product information to over
150,000 Physicians and the distribution network of 1,270 stockiest and 55,000
retailers has the volume handling capability to deliver products to markets in the
fastest possible time.
 Central Warehouse
 22 Clearing & Forwarding (C&F) Agents
 1270 Distributors
 55,000 Retailers
 Cold Chain capability
PARTNERS IN INDIA
Company Product
Therapeutic
category
Year of
partnership
Novartis, India Vildagliptin Diabetes 2008
Roche Xenical Anti-Obesity 2008
Sebapharma,
Germany
Sebamed Cosmeceuticals 2006
Fujix Inc., Japan TripleACal Nutritional 2004
Kissei, Japan Kissei, Japan Diabetes 2006
Engelhard,
Germany
Prospan Respiratory 2005
Alfa Wassermann,
Italy
Fluxum Cardiology 1994
Cimab IORT3 Nephrology 1994
OM Pharma,
Switzerland
Broncho-
Munal
Respiratory 2005
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
8
MANUFACTURING FACILITIES
 US & EU approved solid oral dosages facility
 The EU approved plant for tablets, coated tablets and capsules is state-of-the-art.
Built to cGMP standards and ICH guidelines, it is designed for unidirectional flow
of material.
 The plant offers 6 packaging options including Blister, Strip, Alu-Alu, Pouch,
Bottle packaging and Bulk packaging. Bottle packaging will be available shortly.
 Some highlights of this plant include centralized automated control systems that
detect minor variations in air and temperature levels in sterile zones, building
maintenance and water facilities that conform to international standards, and
back-up systems that ensure minimal downtime.
 Salient features
 Tablets, coated tablets and capsules.
 Built to cGMP standards and ICH guidelines.
 WHO-GMP approved.
 Single shift capacity
o Tablets 3 billion
o Capsules 1.5 billion.
 Approved by National Health Authority of Finland.
 New inject able facility validated by US FDA

DIABETES
 The global prevalence of Diabetes is estimated to increase from 4% in 1995 to 5.4%
by the year 2025.
 Diabetes is steadily assuming epidemic proportions globally. As per IDF Atlas 2003,
a 62% increase in incidence of Diabetes is expected by year 2025.
 Incidence of Diabetes is no longer restricted to the US & Europe.
 In fact, maximal increase in the incidence of Diabetes is observed in the Developing
world. This is corroborated by the following observations:
Continent Year 2003 Year 2025 %
Incidence Estimates Change
SE Asia 39.3 81.6 108
Rest Asia + Aust. 43.0 75.8 76
Africa 7.1 15.0 111
Latin America 14.2 26.2 85
 Family history of Diabetes, Age, Body Mass Index (BMI), waist to hip ratio and a sedentary
life-style showed positive association with diabetes in Indian population.
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
9
 Our existing Brands for Diabetic Treatments
o Duotrol
o Glizide
o Glyboral
o Glycomet
o Glycomet SR
o Glynase
o Glynase MF
o Glynase XL
o GP 1 & 2
o Pioz
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
10
MARKET IN WORLD
 Sri Lanka
 USV ranks 13th among pharmaceutical companies in this market.
 5 brands feature among the top 30 brands (IMS Dec. 08)
 In the OHA segment Metformin and Pioglitazone are leaders.
 In the Cardiovascular disease also USV is leading company.
 Myanmar
 We have a strong presence in the Nutritionals, Cardiovascular & Anti-Diabetes segments
through promotion of our products by an active and aggressive field force. Our
Multivitamins, Piolitazone and Fenofibrate are leaders in their respective segments.
Cambodia
 Our approach in Cambodia is to create an awareness for and acceptance of Chronic Care
segments, that is, Diabetes and Cardiovascular diseases. We have a strong presence in
Multivitamin and Pain Management segments. Our focus is on brand building through an
aggressive sales team and strong distribution.
Singapore
 USV has a strong presence in the diabetes segment in the Diabetes segment. Glycomet the
star product is available in many hospitals through tenders.
AFRICA
 USV present Uganda, Sudan and Kenya. A blend of Cardiology and Anti-diabetes products
along with select Nutritionals are promoted in these countries by Distributors.
 USV will soon be launching products in the Francophone region with business commencing
in Benin, Cameroon, Ivory Coast, Niger and Burkina Faso.
CIS
 USV operates in Kazakhstan and Ukraine through its own field force, working towards
building strong brand equity with leading Endocrinologists and Cardiogolists. USV also a
presence in the Nutritionals and Pain Management segments in these markets.
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
11
Glycomet
Ingredients Each tablet contains metformin 500mg,
850mg, 1000mg
Category
Anti-hyperglycemic, insulin sensitizer
Indications
 Obese/non obese type 2 diabetes
mellitus, as a monotherapy or in
combination with sulfonlyureas,
thiazolidinediones and insulin
 It is also used in type 1 diabetes
along with insulin
 Polycystic ovarian syndrome
Dosage 1/2 tablet to 2 tablets once daily to be taken
before or after meals.
Disclaimer
Products under patents are offered for sale
only in those countries where patents have
expired.
The FDA approved this medication in December, 1994
Countries Trade Name of Glycomet
USA Glucophage, glucophage xr, glumetza
Canada
Apo-metformin, gen-metformin, glucophage,
glycon, novo-metformin, nu-metformin
Mexico Dabex, dimefor, glucophage
Other Countries
Gluformin l, gluformin, bigesens, bigomet,
cetapin, diaformin, diamet, dibeta-sr,
dibimet, e met, emfor, zetfor, zomet,
glyciphage, glycomet.
BRAND – GLYCOMET DETAIL
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
12
GLYCOMET (metformin hydrochloride) Tablets
500 mg Bottles of 100
500 mg Bottles of 500
850 mg Bottles of 100
1000 mg Bottles of 100
GLYCOMET 500 mg tablets
 Round
 White to off-white
 Film-coated tablets debussed with “BMS 6060” around the periphery of the tablet
on one side
 “500” debussed across the face of the other side
GLYCOMET 850 mg tablets
 Round
 White to off-white
 Film-coated tablets debussed with “BMS 6070” around the periphery of the tablet
on one side
 “850” debussed across the face of the other side.
GLYCOMET 1000 mg tablets
 White
 Oval
 Biconvex
 Film-coated tablets with “BMS 6071” debussed on one side and “1000” debussed on
the opposite side
PRODUCT DESIGN
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
13
 A bisect line on both sides
GLYCOMET XR (metformin hydrochloride) Extended-Release Tablets
500 mg Bottles of 100
750 mg Bottles of 100
GLYCOMET XR 500 mg tablets
 White to off-white
 Capsule shaped
 Biconvex tablets
 “BMS 6063” debussed on one side
 “500” debussed across the face of the other side
GLYCOMET XR 750 mg tablets
 Capsule shaped
 Biconvex tablets
 “BMS 6064” debussed on one side
 “750” debussed on the other side
 The tablets are pale red and may have a mottled appearance
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
14
Product Price Quantity
Glycomet 500mg Rs. 12.22 10 Tablets
Glycomet 850mg Rs. 16.40 10 Tablets
Glycomet 1000mg Rs. 32 10 Tablets
Glycomet XR 500mg Rs. 20.24 10 Tablets
Glycomet XR 750mg Rs. 32 10 Tablets
PRICE
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
15
Effective Promotional Strategy
 Advertising media
 Print media (newspaper, magazine, classified ads, brochure)
 Networking
 Business cards
 Tee shirts, hats, buttons, pens
 Printed promotional material
 Audio-visual and computer-based promotional material
 Develop a promotional strategy that uses various media for promoting our brand.
Monitor the different media identifying those that most effectively promote our
brand. Concentrate on developing material for these formats that clearly identifies
our brand.
PRE LAUNCH ACTIVITIES
 The target audience for the horizon scanning and planning information includes:
 NHS(National Health
Service) Commissioners
 Formulary or directorate
pharmacists
 PCT(Primary care trust)
pharmacists
 Senior pharmacy managers
 Directors of Public
Health
 Finance directors
 Chief executives
 National Horizon Scanning
Centre
 Department of Health
 NICE implementation leads
 The target audience for New Medicines Profiles and Therapeutic Class Summaries is:
Medicines information
pharmacists
 Formulary or directorate
pharmacists
 PCT pharmacists  Senior pharmacy managers
 Prescribers from
primary and secondary
care
Prescribing committees
PROMOTIONAL STRATEGY
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
16
POST LAUNCH ACTIVITIES
 Time to market: Worst enemy of the regulator
 Reducing uncertainties that preexist when drugs are taken into the market (long
term outcomes, efficacy/safety in some populations)
 Commitments: which data should be collected post launch?
 Grey zone, not specifically regulated, unclear ownership and funding
 Need for stakeholder collaboration
 Need for incentives: case of personalized (stratified) medicine
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
17
Situational Analysis
 Some of the factors to be considered in conducting a situational analysis are:
 The economic structure of the India and its individual communities
 Topographical and other physical characteristics of the India
 Governmental, public, private, community, and other support systems available
 Characteristics of the population, including:
o Educational levels
o Cultural characteristics
o Life styles and living standards
o Primary occupations
o Income levels
o Communities and their distinguishing characteristics
o Mobility and rates on inflow and outflow of citizens
o Any other aspect of society that may be useful in assessing factors such as
attitudes, motivation, and other characteristics of individual learner groups.
 A useful tool in performing a Situation Analysis is what we might call The C's of
Marketing. The C's of marketing help companies focus on key elements that apply
directly to marketing.
The 5 C's of Marketing can be summarized as:
 Company
 The product time line, experience in the market, etc.
 Collaborators
 Distributors, suppliers, and alliances. These are for companies that you work
with on a day to day basis to help company run.
 Customers
 This is our market. Ask yourself what benefits they are looking for. Where the
customer does actually purchases your product? How the product is purchased
(internet, etc)? Understand the quantity a customer will purchase and even
trends in consumer tastes.
SITUATIONAL & COMPETITIVE
ANALYSIS
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
18
 Competitors
 Both our actual and potential competitors and those that directly or indirectly
compete with us. Understand our products, positioning, market shares,
strengths and weaknesses.
 Climate (or Environment)
 These are governmental policies and regulations that affect the market. It is also
the economic environment around our company; which is the business cycle,
inflation rate, interest rates, and other macroeconomic issues. Society's trends
and fashions are found in the "climate."
Important Factors to Consider in Competitive Analysis
 Define target market.
 Determine the size of the target market.
 Drill down to specific segment within the target market.
 Define the size and the revenue opportunity that segment represents.
 Determine how fast the overall market and specific segment are growing.
 Identify your direct and indirect competitors and understand their impact on you.
 Identify the features that differentiate your product from the competitors.
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
19
Strengths
 Low cost of production
 Large pool of installed capacities
 Efficient technologies for large number of Generics.
 Large pool of skilled technical manpower
 Increasing liberalization of government policies
Opportunities
 Aging of the world population
 Growing incomes
 Growing attention for health
 Saturation point of market is far away
 New therapy approaches
 New delivery systems
 Globalization
 Easier international trading
 New markets are opening
Weakness
 Fragmentation of installed capacities
 Low technology level of Capital Goods of this section
 Non-availability of major intermediaries for bulk drugs
 Lack of experience to exploit efficiently the new patent regime
 Low key R&D
 Low level of strategic planning for future and also for technology forecasting
Threats
 Containment of rising health-care cost
 Stricter registration procedures
 High entry cost in newer markets
 High cost of sales and marketing
 Competition, particularly from generic products
 More potential new drugs and more efficient therapies
 Switching over form process patent to product patent
 Drug Price Control Organization (DPCO)
SWOT ANALYSIS
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
20
To create a brand promise, it should be:
 Grounded in the brand’s core values
 Clearly relevant and engaging to our target market
 Repeated internally and externally within our organization
 Adaptable to the climate
 Continually reinforced
 Consistent across advertising and marketing mediums
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
21
ANTI DIABETIC DRUGS
INGREDIENT NAME
MARKET NAME
COMPANY
NAME
QUANTITY PACKING
PREPARATION OF
METFORMIN
BIGESENS ZYDUS CADILA 500MG 10 TAB XR
1GM 10 TAB XR
BIGOMET
OTSIRA
GENETICA
250MG 10TAB
500MG 10TAB
850MG 10TAB
500MG 10 TAB SR
1000MG 10 TAB SR
CETAPIN AVENTIS 500MG 10TAB
D-BAY ARGUS 500MG 10TAB
850MG 10TAB
DAOMET JB CHEMICAL 500MG 10 TAB SR
100MG 10 TAB SR
DIAFORMIN CFL 500MG 10TAB
DIAMET BAL PHARMA 500MG 10TAB
850MG 10TAB
500MG 10 TAB SR
1000MG 10 TAB SR
DIBETA-SR 500 TORRENT 500MG 10 TAB SR
1GM 10 TAB SR
DIBIMET NOVARTIS 500MG 10TAB
EMET
ELEGANT
DRUGS
500MG 10TAB
EMFOR STADMED 500MG 10TAB
ANTI DIABETIC DRUGS – EXISTING
BRANDS (SOURCE – INDIAN DRUG
RECORD)
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
22
EMNORM IPCA 250MG 10TAB
500MG 10TAB
850MG 10TAB
ETFORMIN DEYS 500MG 10TAB
FORMET
CHEMECH
LABS
500MG 10TAB
1GM 10 TAB SR
FORMIN ALKEM 500MG 10TAB
850MG 15 TAB
FORMIN-500 STATMED 500MG 10TAB
FORMINAL ALEMBIC 500MG 10TAB
850MG 10TAB
GLUFORMIN NPIL 500MG 10TAB
850MG 10TAB
GLUFORMIN XL NPIL 500MG 10 TAB XR
1000MG 10 TAB XR
GLUMET PROTEC 500MG 10TAB
850MG 10TAB
GLUMET-XR PROTEC 500MG 10 TAB XR
GLYCIPHAGE
FRANCO
INDIAN
250MG 10TAB
500MG 10TAB
850MG 10TAB
500MG 10 TAB SR
GLYCOMET USV 500MG 10TAB
850MG 10TAB
1GM 10 TAB SR
GLYREP EMCURE 500MG 10TAB
1GM 10TAB
INSUMET
CADILA
PHARMA
500MG 10TAB
850MG 10TAB
500MG 10 TAB SR
MELMET MICRO LABS 500MG 10TAB
METCHEK RADIUS 500MG 10TAB
850MG 10TAB
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
23
METCOM COMED 500MG 10TAB
850MG 10TAB
METLONG PANACEA 500MG 10TAB
METMIN JENBURKT 500MG 10 TAB
MF-SR PIL 500MG 10 TAB SR
1GM 10 TAB SR
RIOMET OD RANBAXY CV 500MG 10TAB
1GM 10TAB
WALAPHAGE WALLACE 500MG 10 TAB
850MG 10 TAB
XMET HEALTHEON 250MG 10 TAB
500MG 10 TAB
850MG 10 TAB
ZETFOR RAPTAKOS 500MG 10 TAB
850MG 10 TAB
500MG 10 TAB CR
ZOMET INTAS 500MG 10 TAB
850MG 10 TAB
500MG 10 TAB SR
1000MG 10 TAB SR
COMBINATION OF
METFORMIN &
GLIBENCLAMIDE
BENCLAMET
RPG LIFE
SCIENCE
METFORMIN
400MG
10 TAB
GLIBENCLAMID
E 2.5MG
BENCLAMET
FORTE
RPG LIFE
SCIENCE
METFORMIN
500MG
10 TAB
GLIBENCLAMID
E 5MG
DIABETROL NPIL
METFORMIN
500MG
10 TAB
GLIBENCLAMID
E 5MG
DUOTOROL USV
METFORMIN
500MG
10 TAB
GLBENCLAMIDE
5MG
GLIBOMET
MENARINI
RAUNAQ
METFORMIN
HCL 400MG
10 TAB
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
24
GLIBENCLAMID
E 2.5MG
GLIBOMET FORT
MENARINI
RAUNAQ
METFORMIN
HCL 500MG
10 TAB
FORTE
GLIBENCLAMID
E 5MG
GLUCONIL-M BAL PHARMA
METFORMIN
HCL 500MG
10 TAB
GLIBENCLAMID
E 5MG
GLUCORED SUN PHARMA
METFORMIN
400MG
10 TAB
GLIBENCLAMID
E 2.5MG
METFORMIN
500MG
10 TAB
FORTE
GLIBENCLAMID
E 5MG
GLUCOTRAC INTRA LABS
METFORMIN
400MG
10 TAB
GLIBENCLAMID
E 2.5MG
GLUCOTRAC PLUS INTRA LABS
METFORMIN
500MG
10 TAB
GLIBENCLAMID
E 5MG
GLYCURB / FORT
WIN
MEDICARE
METFORMIN
400MG
8*7 TAB
GLIBENCLAMID
E 2.5MG
METFORMIN
500MG
8*7 TAB
GLIBENCLAMID
E 5MG
MELITUS NPIL
METFORMIN
400MG
10 TAB
GLIBENCLAMID
E 2.5MG
SUGATROL ARGUS
METFORMIN
400MG
10 TAB
GLIBENCLAMID
E 2.5MG
COMBINTION OF
METFORMIN & GLIPIZIDE
BIMODE-M
NUCRON
PHARMA
METFORMIN
400MG
10 TAB
GLIPIZIDE
2.5MG
DIACON-M BAL PHARMA
METFORMIN
500MG
10 TAB
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
25
GLIPIZIDE 5MG
DIACON-M BAL PHARMA
METFORMIN
500MG
10 TAB
GLIPIZIDE 5MG
GLIMET DS
FRANCO
INDIAN
METFORMIN
250MG
10 TAB
GLIPIZIDE
2.5MG
GLIPIMET AZTEC
METFORMIN
400MG
10 TAB
GLIPIZIDE
2.5MG
GLUCOTROL-MF JENBURKT
METFORMIN
HCL 500MG
10 TAB
GLIPIZIDE 5MG
GLYNASE MF USV
METFORMIN
500MG
10 TAB
GLIPIZIDE 5MG
LIPI-M DEYS
METFORMIN
500MG
10 TAB
GLIPIZIDE 5MG
METAGLEZ/FORT
E
OTSIRA
GENETICA
METFORMIN
HCL 400MG
10 TAB
GLIPIZIDE
2.5MG
METGLIB-500 TAURUS LABS
METFORMIN
500MG
10 TAB
GLIPIZIDE 5MG
TRANASE-MF INTRA LABS
METFORMIN
500MG
10 TAB
GLIPIZIDE 5MG
ZIDMIN TRIDOSS
METFORMIN
500MG
10 TAB
GLIPIZIDE 5MG
COMBINATION OF
METFORMIN &
GLICLAZIDE
AZUKON-M TORRENT
METFORMIN
500MG
10 TAB
GLICAZIDE
80MG
COMZID-M COMED
METFORMIN
HCL 500MG
10 TAB
GLICAZIDE
80MG
DIABEND-M BAL PHARMA METFORMIN 10 TAB
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
26
500MG
GLICAZIDE
80MG
DIANORM-M CARSYON
METFORMIN
500MG
10 TAB
GLICAZIDE
80MG
DIATROL-M ARGUS
METFORMIN
5OOMG
10 TAB
GLICAZIDE
80MG
EUCLIDE-M ALKEM
METFORMIN
500MG
10 TAB
GLICAZIDE
80MG
GLICAMET BIOCHEM
METFORMIN
HCL 500MG
10 TAB
GLICAZIDE
80MG
GLICLAZ-M KHANDELWAL
METFORMIN
500MG
10 TAB
GLICAZIDE
80MG
GLIDIET-M
MODI-MUNDI
PHARMA
METFORMIN
500MG
10 TAB
GLICAZIDE
80MG
GLIDIET-M
WIN
MEDICARE
METFORMIN
500MG
10 TAB
GLICAZIDE
80MG
GLIZA-MF STADMED
METFORMIN
HCL 500MG
10 TAB
GLICAZIDE
80MG
GLIZID-M PANACEA
METFORMIN
500MG
10 TAB
GLICAZIDE
80MG
GLUCOFIT-M RAPTAKOS
METFORMIN
HCL 500MG
10 TAB
GLICAZIDE
80MG
GLUCOZID-M
MEDLEY
PHARMA
METFORMIN
HCL 500MG
10 TAB
GLICAZIDE
80MG
GLYCHEK-M INDOCO
METFORMIN
HCL 500MG
10 TAB
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
27
GLICAZIDE
80MG
GLYCIGON-M ARISTO
METFORMIN
500MG
10 TAB
GLICAZIDE
80MG
GLYCINORM-M
8OMG
IPCA
METFORMIN
500MG
10 TAB
GLICAZIDE
80MG
GLYGARD-M CIPLA
METFORMIN
HCL 500MG
10 TAB
GLICAZIDE
80MG
GLYKIND-M
MANKIND
PHARMA
METFORMIN
500MG
10 TAB
GLICAZIDE
80MG
GLYLOC-M
CADILA
PHARMA
METFORMIN
HCL 500MG
10 TAB
GLICAZIDE
80MG
GLERED-M NOVARTIS
METFORMIN
HCL 500MG
10 TAB
GLICAZIDE
80MG
GLZ PLUS ALEMBIC
METFORMIN
500MG
10 TAB
GLICAZIDE
80MG
LIZ-M DEY'S
METFORMIN
500MG
6 TAB
GLICAZIDE
80MG
LYCAZID-M JAGSONPAL
METFORMIN
HCL 500MG
1O TAB
GLICAZIDE
80MG
MINTIDE
VENUS
REMEDIES
METFORMIN
HCL 500MG
10 TAB
GLICAZIDE
80MG
NUZIDE-M INTAS
METFORMIN
500MG
1O TAB
GLICAZIDE
80MG
RECLIMET
DR. REDDY'S
LAB
METFORMIN
500MG
10 TAB
GLICAZIDE
80MG
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
28
WALFORMIN WALLACE
METFORMIN
HCL 500MG
10 TAB
GLICAZIDE
80MG
ZYDE-MF PIL
METFORMIN
HCL 500MG
10 TAB
GLICAZIDE
80MG
COMBINATION OF
METFORMIN WITH
GLIMEPRIDE
AZULIX 1/2 MF NOVARTIS
METFORMIN
500MG
10 TAB
GLIMEPRIDE
1MG
AZULIX 1/2 MF
FORTE
TORRENT
METFORMIN
1000MG
10 TAB
GLIMEPRIDE
1MG
BETAGRIM-M PANACEA
METFORMIN
500MG
10 TAB
GLIMEPRIDE
1MG
DAORYL-M JB CHEMICAL
METFORMIN BI
LAYERED
TABLET
10 TAB
GLIMEPRIDE
1MG
EUGLIM-M-1/2 ZYDUS CADILA
METFORMIN
500MG
10 TAB
GLIMEPRIDE
1MG
GLIMIPREX-MF
(SUSTAIN
RELEASE)
OTSIRA
GENETICA
METFORMIN
500MG
10 TAB
GLIMEPRIDE
1MG
GLIMPIL-MF (SR) PIL
METFORMIN
500MG
10 TAB
GLIMEPRIDE
1MG
GLISTA M1/M2
(SR)
CADILA
PHARMA
METFORMIN
500MG
10 TAB
GLIMEPRIDE
1MG
GLM (SR) SYSTOPIC
METFORMIN
500MG
10 TAB
GLIMEPRIDE
1MG
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
29
GLUFORMIN
G1/G2-SR
NPIL
METFORMIN
500MG
10 TAB
GLIMEPRIDE
1MG
GMT-SR INDOCO
METFORMIN
500MG
10 TAB
GLIMEPRIDE
1MG
METRIDE-SR UNISEARCH
METFORMIN
500MG
10 TAB
GLIMEPRIDE
1MG
METRIDE PLUS UNISEARCH
METFORMIN
500MG
10 TAB
GLIMEPRIDE
1MG
PIOGLITAZONE
15MG
PRICHEK-M INDOCO
METFORMIN
500MG
10 TAB
GLIMEPRIDE
1MG
ZORYL M - SR INTAS
METFORMIN
500MG
10 TAB
GLIMEPRIDE
1MG
COMBINATION OF
METFORMIN WITH
ROSIGLITAZONE
ENSELIN 2MF TORRENT
METFORMIN
500MG
10 TAB
ROSIGLITAZONE
2MG
ENSELIN-4MF TORRENT
METFORMIN
500MG
10 TAB
ROSIGLITAZONE
4MG
ENSELIN 2MF
FORTE
TORRENT
METFORMIN
1000MG
10 TAB
ROSIGLITAZONE
2MG
ENSELIN 4MF
FORTE
TORRENT
METFORMIN
1000MG
10 TAB
ROSIGLITAZONE
4MG
REZULT-M AZTEC(SUN)
METFORMIN
500MG
10 TAB
ROSIGLITAZONE
2MG
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
30
REZULT M4 AZTEC(SUN)
METFORMIN
500MG
10 TAB
ROSIGLITAZONE
4MG
ROGLIN-M2 ARISTO
METFORMIN
500MG
10 TAB
ROSIGLITAZONE
2MG
ROGLIN-M4 ARISTO
METFORMIN
500MG
10 TAB
ROSIGLITAZONE
4MG
ROSICON-MF HEALTHEON
METFORMIN
500MG
10 TAB
ROSIGLITAZONE
2MG
ROSIMET PANACEA
METFORMIN
500MG
10 TAB
ROSIGLITAZONE
2MG
ROSINORM-M MICRO LABS
METFORMIN
500MG
10 TAB
ROSIGLITAZONE
2MG
ROSIZON-MT EMCURE
METFORMIN
500MG
10 TAB
ROSIGLITAZONE
4MG
COMBINATION OF
METFORMIN WITH
PIOGLITAZONE
G-TASE M-ER UNISEARCH
METFORMIN
500MG
10 TAB
PIOGLITAZONE
15MG
GLITA-M-CR STADMED
METFORMIN
500MG
10 TAB
PIOGLITAZONE
15MG
GLIZONE M 15/30 ZYDUS CADILA
METFORMIN
500MG
10 TAB
PIOGLITAZONE
15MG
PIANORM-M-CR CARSYON
METFORMIN
500MG
10 TAB
PIOGLITAZONE
15MG
PIOGLAR-M STANCARE
METFORMIN
500MG
10 TAB
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
31
PIOGLITAZONE
30MG
PIOGLIT-MF SUN PHARMA
METFORMIN
500MG
10 TAB
PIOGLITAZONE
7.5MG
PIOKAP MF KAPL
METFORMIN
500MG
10 TAB
PIOGLITAZONE
15MG
PIOGLU-M EMCURE
METFORMIN
500MG
10 TAB
PIOGLITAZONE
30MG
PIOLET M SR INTAS
METFORMIN
500MG
10 TAB
PIOGLITAZONE
15MG
PIOSAFE-MF SR
OTSIRA
GENETICS
METFORMIN
500MG
10 TAB
PIOGLITAZONE
15MG
PIOZONE M NPIL
METFORMIN
500MG
10 TAB
PIOGLITAZONE
15MG
PIOZULIN M15 SR
CADILA
PHAARMA
METFORMIN
500MG
10 TAB
PIOGLITAZONE
15MG
PIOZULIN M30 SR
CADILA
PHAARMA
METFORMIN
500MG
10 TAB
PIOGLITAZONE
30MG
PIZORAD-MSR RADIUS
METFORMIN
500MG
10 TAB
PIOGLITAZONE
15MG
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
32
SALES PLANNING FOR THE SALES MANAGER
 Following steps are required for building a Winning Sales Plan
 Summarize our Objectives
 Identify the Strategic Objectives
 Assess Prior Sales Performance
 Segment our Customers
 Set This Year's Objectives
 Develop Territories Action Plans
 Develop Key Accounts Plans
 Measure and Monitoring Results
 Establish our Annual Sales Planning Cycle
 Write the Executive Summary
 There are three primary sections to the Sales Plan:
 Understand our Sales Objectives
 Develop our Action Plans
o Rep Territory Plans
o Rep Key Account Plans
 Measure and Report our Results
 The next page outlines how the Sales Plan that we will develop fits into the overall
planning requirements of the business.
SALES PLAN
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
33
Understand our Sales Objectives
 Identify the Sales objectives:
 To present an overview of our brand's sales objectives as they are defined in our
objectives.
 This introductory section of our Sales Plan requires us to identify the specific overall
sales objectives as reflected in the annual plan. The purpose of this exercise is to
ensure that we clearly understand the sales requirements of the brand plan on a
quarterly basis and the company's overall brand planning objectives.
 The template that is on the next page is a generic table that should be modified and
filled in to reflect the specific definitions of our own products. This particular
template defines the quarterly sales objectives for products in terms of sales
revenue, units and market share. In fact, we may have just one product and
additional objectives that we monitor.
 Objectives:
 Modify this template to fit our own requirements and fill in the Sales Revenue
numbers, the unit Sales numbers and the market share percentages by quarter.
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
34
Category Q1 Q2 Q3 Q4 Total
Total Sales(Rs)
Sales of Glycomet 500mg
Unit Sales of Glycomet 500mg
Sales of Glycomet 850mg
Unit Sales of Glycomet 850mg
Sales of Glycomet 1000mg
Unit Sales of Glycomet 1000mg
Sales of Glycomet XR 500mg
Unit Sales of Glycomet XR 500mg
Sales of Glycomet XR 750mg
Unit Sales of Glycomet XR 750mg
Market Share of Glycomet 500mg
% % % % %
Market Share of Glycomet 850mg
% % % % %
Market Share of Glycomet 1000mg
% % % % %
Market Share of Glycomet XR 500mg
%
% % % %
Market Share of Glycomet XR 750mg
%
% % % %
Summarize the existing sales performance
 Objective of this section is to present the sales data that identifies...
 The historical sales performance during the past one to three years depending on
the specific performance criteria, and...
 The current sales performance.
 The intent of this section is to help understand the current perspective of the sales
and market share performance of the company.
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
35
 The information displayed in below graphs should set the stage that will enable us
to set this year's objectives.
 Outlined below are specific sales performance templates of graphs and tables that
should be modified to reflect our own products and the types of objectives that we
report.
Total Net Sales: 5 years history / this year's BUSINESS PLAN
 The first graph outlines total net sales (in this example by Rs) for the prior five years
with the current BRAND PLAN projection of sales for 2010-2011.
 Having displayed in the prior graph a baseline of historical annual performance and
compared this to this year's BRAND PLAN objective, this next graph would display
the prior year's sales performance by quarter compared to the sales plan objectives.
 The use of this data is to graphically show us how the sales results have trended
during the prior year and provide us with a guideline for setting our quarterly
objectives for this upcoming year.
2005
2006
2007
2008
2009
2010
7.5 8 10.3 11 13
7 9 10
13 15
25
Total Net Sales By Year: Actual to Plan
Actual Sale(Rs. In Cr) Plan Sale (Rs. In Cr)
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
36
 Market Share Graphs:
 These graphs quickly display the positioning of our products compared to those of
our competitors. Again, this information provides us with an historical baseline
enabling us to more productively create our own objectives for this upcoming year.
 Market Share Trend
 This first displays an easy-to-read bar graph of market share growth over the
period of the prior four years.
2009 Q1
2009 Q2
2009 Q3
2009 Q4
1.5
2.5
4
5
2.5 3
4
5.5
Sales Result For Prior Year By Quarter
Compared To Plan
Actual Sales(Rs. In Cr) Plan Sales (Rs. In Cr)
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
37
Develop our Actions Plans
 We will establish the objectives, the tactics and the primary action plans that will be
used by us and by our Sales Representatives during the entire year. It is also in this
section that we will work with our Sales Representatives to create their Territory
Plans and their Key Account Plans.
Segment our Customers
 Segmentation Tiers
 Objective of this is to present specific examples of customer segmentations as they
relate to...
o The numbers of target customers in each tier, and
o The number of end users in each tier.
 Segmentation by customer classifications should be used as a tool for us to...
o Plan the specific type of sales tactics that we will use for each tier.
o Determine the sales call frequency patterns that will be applied to each tier.
 We should modify our own customer segmentation depending on...
o The overall number of customers in our territory, and
2006
2007
2008
2009
2
4
6 7
6
5
8
10
5 5.5 7 8
8
10.3 11
13
Market Share Trend Over 4 Prior Years
Zydus Cadila (Bigesens) Aventis (Cetapin) Novartis (Dibimet) USV (Glycomet)
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
38
o The level of the complexity of the sale process, and
o The maturity of our products in our markets.
Create our Reach & Frequency Objectives
 Objective of this is to present the monthly sales call frequency patterns that are
expected of our Sales Representatives.
Set This Year's Objectives
 Objective of this section is to define the specific annual sales objectives in a clear and
easy-to-understand manner which is both highly quantifiable and qualitative.
Revenue and Market Share Objectives:
J F M Q1 A M J Q2 J A S Q3 O N D Q4 Total
Total Sales
Sales in Rs
of
Glycomet
500 mg
Sales Unit
of
Glycomet
500mg
Tiers
Number of
physician's
Number
of calls
per
month
Priority
1
2
3
4
Totals
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
39
Sales in Rs
of
Glycomet
850 mg
Sales Unit
of
Glycomet
850mg
Sales in Rs
of
Glycomet
1000 mg
Sales Unit
of
Glycomet
1000mg
Sales in Rs
of
Glycomet
XR 500 mg
Sales Unit
of
Glycomet
XR 500mg
Sales in Rs
of
Glycomet
XR 750 mg
Sales Unit
of
Glycomet
XR 750mg
Market
share of
Glycomet
500mg
Market
share of
Glycomet
850mg
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
40
Market
share of
Glycomet
1000mg
Market
share of
Glycomet
XR 500mg
Market
share of
Glycomet
XR 750mg
Set our End User Objectives
 Objective of this is to define the specific monthly and quarterly end user objectives
in a clear and easy-to-understand manner which is highly quantifiable. One of these
tables should be completed for each product.
 In the table shown below, the term, "Baseline" has been used to define the total end
user population that we are beginning with."New" end users refer to the number of
end users who have not previously been on any therapy. "Switched" end users refer
to those end users that have transitioned from a competitor's product.
J F M Q1 A M J Q2 J A S Q3 O N D Q4 Total
End
Users
Base Line
New
Switches
Total
Set our Customer Objectives
 Objective of this is to define the specific monthly and quarterly customer objectives
in a clear and easy-to-understand manner which is highly quantifiable. One of these
tables should be completed for each product.
 In the table shown below, the term, "Baseline" has been used to define the total
customer population that we are beginning with. "New “customers refer to the
number of customers added each month. "Lost” customers refer to those customers
that have transitioned from our product to a competitor's product.
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
41
J F M Q1 A M J Q2 J A S Q3 Oct N D Q4 Total
Customer
Base Line
New
Lost
Total
Plan our Sales Force Structure
 Objective of this is to define the critical objectives as they relate to the hiring,
training and development of our Sales Manager, and our Sales Representatives.
Organizational Structure
 Objective of this is to graphically show the planned organizational structure for this
year.
 Shown below is a simple table of a structure that is currently being employed at a
business unit level.
Plan of Hiring Timetable
 Objective of this is to identify...
 When the hiring process will begin, and
 When the position will be filled, and
 When the training will take place, and
 The timing for revenue impact in the territory.
Hiring Plan
 The following is a table of a hiring plan that should be developed over the period of
our brand Plan.
 We should identify in the table below the quarter in which we must have in place
any new hires that are required to make our plan successful.
 The purpose of this table is to create a visual map of our hiring plan for the entire
year.
 The next step in this process is for us to develop a detailed recruiting and training
timetable that will provide the back up for these dates.
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
42
Hiring Table
Positions Q1 Q2 Q3 Q4 Total
List any
manager
positions
List the
specific rep
territories
(number
of
people)
List any
staff
positions
Recruiting, Hiring and Training Table
 Now that we have defined the quarterly timetable for our expansion or for our
replacement hires during the year, we need to fill in the monthly table below with
the various components of the hiring process to ensure our hiring objectives, and
therefore, our sales objectives will be met.
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
43
Recruiting, Hiring and Training Table
Category
Month
1
Month
2
Month
3
Month
4
Month
5
Month
6
Profile
Position
Confirm
approval
Hire
Recruiter
Screening
Interviewing
Training
Internal
Training
Field
Monitor
performance
Fully
Productive
Review
performance
Plan our Training Needs and Requirements:
 This details the training requirements for the following categories...
 All new sales and marketing hires.
 Developmental management training and education for our sales and marketing
Manager.
 Developmental sales and marketing skills training for our existing Representatives.
 Developmental clinical training for our existing Representatives.
 Other than the training for new hires, this training should be based on the job
requirements of the various positions and our assessment of our current
Representatives that some of them may not adequately fill those requirements. This
inability may be due to a lack of experience or exposure or training.
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
44
 Questions to be asked:
 Is there any product related information that my sales force or I require to exceed
our objectives?
 Is there any company related information that my sales force must know to remain
well informed?
 Is there any new competitive information my sales force needs that will assist them
in exceeding our objectives?
 Are there any areas of weakness in sales skills, clinical knowledge, territory
knowledge or account management skills that can be taught or reinforced through
training?
 Are there skills that I need to improve my capabilities of sales management?
Total Number of customers within territory
Number of target customers as a percentage of total %
Coverage of target customers (YTD) %
Number of accounts in territory %
Number of target accounts as a percentage of total %
Daily Call Average
Training Requirements
Training Requirements
Category Jan Feb Mar Apr May Jun July Aug Sep Oct Nov Dec
Sales Manager
Development
of Education
Management
Skills Training
New Hires
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
45
New Hire
Training
Current Reps
Product
Training
Clinical
Training
Sales Skills
Training
Plan our Incentive Packages
 This outlines the primary components of our annual incentive planning for our
Representatives.
Sales Representatives Incentive Planning
 Before we begin to detail our incentive plan, we need to answer the following
questions in as much detail as possible in order to ensure clarity not only for we but
also for our Representatives and any other associated departments, such as
Personnel and Finance, who will review and work with our incentive plan.
 Answers to the following questions should be filled in as part of our Sales Plan.
 The questions that should be answered here are similar to those above for the
following...
 What are the Objectives of our Incentive Plan?
 What are the Measurements?
 What are the Criteria that will be used?
 What is the Time Frame?
 What is the Pawet Table?
 What is the Eligibility?
Awards Programs
 In addition to the annual incentive plan we have detailed above, the purpose of this
section is to identify the primary incentive and award programs that will occur
during the year and their proposed timetable. These may be specific incentive
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
46
programs that are annual or quarterly, or award programs that will be given at
national sales meetings.
 Examples are: Sales Rep of the Year, Sales Rookie of the Year, and Council of
Excellence.
Incentive
Program
Description Territories Month
Opportunity Segments
What are the Opportunities? What are the Primary Tactics?
Obj.
Tactics or
Action Items
Budget or
Resources Required
Return on
Investment Criteria
Month to be
Completed
1.
2.
3.
4.
5.
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
47
Report & Monitor
 This section details the monthly reporting requirements.
Recommended Monthly Reports
 The importance of monthly reports is that they should provide an effective and
efficient means of communicating results. Monthly reports should be developed by
both we as well as the Sales Manager and by our individual Representatives.
 Reports should be consistent in their format since they are going to be used as
communication tools to a number of people in a variety of departments.
 Reports should be short, concise and to the point detailing performance against
objectives, primary accomplishments and items of primary interest.
 Reports should be detailed and heavily quantifiable reporting both objectives and
results.
 Reports should be proactive rather than reactive and should avoid defining history
"for the record".
 Reports must be regarded as a useful tool and not "busy work"; therefore, they
should be equally easy-to-complete and easy-to-read.
 We can provide them with examples of a planning and monitoring format that have
been used during the past year and proven to be a very effective tool among a large
sales force.
 They are typically the monthly report formats that are used by US Regional
Directors.
 These particular formats resulted from the Regional Directors working together to
define a reporting and monitoring tool that would be useful to them as managers
and useful as a communication vehicle for information given to other departments.
REPORT AND MONITOR
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
48
monthly sales report/forecast (template)
Sales
dept/tea
m ………….
Month
…………
This basic sales report/forecast tool is for a small or new businesses which do not yet have a
computerized full management information system, which would normally integrate sales reporting
with other business processes.
Month cumulative (year to date)
sales for month actual Plan variance %
actua
l
plan variance %
volumes/quantity/number
number of orders
average order value
next month forecast f'cast Plan variance % f'cast plan variance %
volumes/quantity/number
number of orders
average order value
quarter forecast f'cast Plan variance % f'cast plan variance %
volumes/quantity/number
number of orders
average order value
year forecast f'cast Plan variance % f'cast plan variance %
volumes/quantity/number
number of orders
average order value
summary/forecast of sales performance and activities
comments on internal services affecting sales and customers (e.g., order processing, customer services,
stock, distribution and deliveries/installations, service support, invoicing, major/national contracts,
new product development, recruitment and training, etc)
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
49
competitor activity
market comments (trends, developments, SWOT factors of note, i.e., strengths, weaknesses,
opportunities, threats)
Report compiled by ……………...………..….. Date ………………..
Leading and Lagging Indicators
 It is recommend that we need to monitor both the "Leading" and the "Lagging"
Indicators on a daily, weekly and monthly basis in order to track and consistently
forecast the performance of our brand. By tracking these results in this manner, we
keep our self fully knowledgeable of what is happening in the field and ensure that
we and our brand will not be surprised.
 Provided below are examples of indicators that we should consider monitoring:
 We recommend that we begin this monitoring system formally, but use only a
limited number of indicators to begin in order to assure that the process of data
collection and reporting actually takes place consistently. Nothing would be more
confusing to our management efforts than to begin this tracking process and then
abandon because it became too difficult to administer.
Leading Indicators to Monitor
Daily Sales Flash of ex-factory (shipments) sales
Wholesaler inventory levels
New end user referrals
Sales rep reports on new business
Sales rep call activity reports
Red Alerts: Competitive activity, reimbursement changes
Red Alerts: Flag specific customer sales which drop >10%
Field requests for marketing materials
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
50
Lagging Indicators to Monitor
Wholesaler outflow data
Market demand data
Reimbursement (Medicaid-US) claims data
Pharmacy stocking reports
IMS data
Tier movement data
Primary market research
Define our Annual Planning Cycle
 To define and outline the components of the annual planning cycle: The purpose of
the following table is for we to plan out the primary planning activities for we as
Manager and for our Representatives over the period of eighteen months.
Planning Cycle
Required
Input
J F M A M J J A S O N D J F M A M J J
Input to
Marketing
Plan
Create
First
rough
draft of
National
Sales Plan
Submit
Budgets
Plan
Approvals
Complete
final
National
Sales Plan
Complete
all
Regional
and
territory
Plans
BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN)
PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL
51
Complete
Target
Account
Plans
Sales
Meetings
National
Meetings
Regional
Meetings
Territory
Meetings

Weitere ähnliche Inhalte

Was ist angesagt?

New launching strategy of pharmaceutical brand
New launching strategy of pharmaceutical brandNew launching strategy of pharmaceutical brand
New launching strategy of pharmaceutical brandMohammad Masum Chowdhury
 
Brand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XBrand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XSatyajit Hui
 
Marketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA ProgramMarketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA Programjreidglass1
 
Marketing Plan of Esomeprazole
Marketing Plan of EsomeprazoleMarketing Plan of Esomeprazole
Marketing Plan of EsomeprazoleAnimesh Gupta
 
Brand plan on cough syrup
Brand plan on cough syrup Brand plan on cough syrup
Brand plan on cough syrup Animesh Gupta
 
Globifer brand plan
Globifer brand planGlobifer brand plan
Globifer brand planMRINMOY ROY
 
Marketing of a pharma (Basic)
Marketing of a pharma (Basic)Marketing of a pharma (Basic)
Marketing of a pharma (Basic)Arsalan Humayun
 
Voltaren campaign || A.TANTAWY
Voltaren campaign || A.TANTAWYVoltaren campaign || A.TANTAWY
Voltaren campaign || A.TANTAWYAbdelrhman Tantawy
 
Hexgabalin pharmaceutical marketing plan - case study
Hexgabalin  pharmaceutical marketing plan - case studyHexgabalin  pharmaceutical marketing plan - case study
Hexgabalin pharmaceutical marketing plan - case studyAbdelrhman Tantawy
 
Pharma marketing
Pharma marketingPharma marketing
Pharma marketingUzair Ahmed
 
Pharmaceutical Marketing Strategy
Pharmaceutical Marketing StrategyPharmaceutical Marketing Strategy
Pharmaceutical Marketing StrategyAwais e Siraj
 
How to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing PlanHow to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing PlanMuhammad Ali Jehangir
 
Pharmaceutical Marketing Case Study
Pharmaceutical Marketing Case StudyPharmaceutical Marketing Case Study
Pharmaceutical Marketing Case StudyNiranjan Somathilaka
 
Dispercam Marketing Plan @AxTantawy
Dispercam Marketing Plan @AxTantawyDispercam Marketing Plan @AxTantawy
Dispercam Marketing Plan @AxTantawyAbdelrhman Tantawy
 

Was ist angesagt? (20)

New Launch Strategy & Product Cycle
New Launch Strategy & Product CycleNew Launch Strategy & Product Cycle
New Launch Strategy & Product Cycle
 
Pharma brand plan
Pharma brand planPharma brand plan
Pharma brand plan
 
New launching strategy of pharmaceutical brand
New launching strategy of pharmaceutical brandNew launching strategy of pharmaceutical brand
New launching strategy of pharmaceutical brand
 
Brand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XBrand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-X
 
Marketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA ProgramMarketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA Program
 
Marketing Plan
Marketing PlanMarketing Plan
Marketing Plan
 
Marketing Plan of Esomeprazole
Marketing Plan of EsomeprazoleMarketing Plan of Esomeprazole
Marketing Plan of Esomeprazole
 
Esomeprazole plan
Esomeprazole planEsomeprazole plan
Esomeprazole plan
 
Brand plan on cough syrup
Brand plan on cough syrup Brand plan on cough syrup
Brand plan on cough syrup
 
Etizola brand plan
Etizola brand planEtizola brand plan
Etizola brand plan
 
Globifer brand plan
Globifer brand planGlobifer brand plan
Globifer brand plan
 
Marketing of a pharma (Basic)
Marketing of a pharma (Basic)Marketing of a pharma (Basic)
Marketing of a pharma (Basic)
 
Voltaren campaign || A.TANTAWY
Voltaren campaign || A.TANTAWYVoltaren campaign || A.TANTAWY
Voltaren campaign || A.TANTAWY
 
Hexgabalin pharmaceutical marketing plan - case study
Hexgabalin  pharmaceutical marketing plan - case studyHexgabalin  pharmaceutical marketing plan - case study
Hexgabalin pharmaceutical marketing plan - case study
 
Pharma marketing
Pharma marketingPharma marketing
Pharma marketing
 
Diclofenac Injection BRAND PLAN
Diclofenac Injection BRAND PLANDiclofenac Injection BRAND PLAN
Diclofenac Injection BRAND PLAN
 
Pharmaceutical Marketing Strategy
Pharmaceutical Marketing StrategyPharmaceutical Marketing Strategy
Pharmaceutical Marketing Strategy
 
How to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing PlanHow to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing Plan
 
Pharmaceutical Marketing Case Study
Pharmaceutical Marketing Case StudyPharmaceutical Marketing Case Study
Pharmaceutical Marketing Case Study
 
Dispercam Marketing Plan @AxTantawy
Dispercam Marketing Plan @AxTantawyDispercam Marketing Plan @AxTantawy
Dispercam Marketing Plan @AxTantawy
 

Andere mochten auch

Pharmaceutical Marketing Management
Pharmaceutical Marketing ManagementPharmaceutical Marketing Management
Pharmaceutical Marketing ManagementSheraz Pervaiz
 
Pharma Plan Presentation Powerpoint
Pharma Plan Presentation PowerpointPharma Plan Presentation Powerpoint
Pharma Plan Presentation Powerpointwaschmaschine
 
Beloved brands-brand-plan
Beloved brands-brand-planBeloved brands-brand-plan
Beloved brands-brand-planPreetam Sakpal
 
I've Got Nothing To Tell About My Brand!
I've Got Nothing To Tell About My Brand!I've Got Nothing To Tell About My Brand!
I've Got Nothing To Tell About My Brand!The Story House
 
Apresentação vip calçados
Apresentação vip calçadosApresentação vip calçados
Apresentação vip calçadosvipcalcados
 
Navicor Corporate Brochure
Navicor Corporate BrochureNavicor Corporate Brochure
Navicor Corporate BrochureDave Querry
 
The Math Behind Your Blog
The Math Behind Your BlogThe Math Behind Your Blog
The Math Behind Your BlogMike Seidle
 
Visual Storytelling-Drive Social Media Engagement
Visual Storytelling-Drive Social Media EngagementVisual Storytelling-Drive Social Media Engagement
Visual Storytelling-Drive Social Media EngagementLeonardo
 
19 reasons why pharma marketing should start with telling the story of their ...
19 reasons why pharma marketing should start with telling the story of their ...19 reasons why pharma marketing should start with telling the story of their ...
19 reasons why pharma marketing should start with telling the story of their ...The Story House
 
Brand strategy executive summary slideshare
Brand strategy executive summary slideshareBrand strategy executive summary slideshare
Brand strategy executive summary slideshareTony Monda
 
What If Everyone Understood Your Brand Plan?
What If Everyone Understood Your Brand Plan?What If Everyone Understood Your Brand Plan?
What If Everyone Understood Your Brand Plan?The Story House
 
Patient profiling disaggregating the data
Patient profiling disaggregating the dataPatient profiling disaggregating the data
Patient profiling disaggregating the datanhsnwHELP
 
Brand plan..salbutamol.by himanshu tripathi
Brand plan..salbutamol.by himanshu tripathiBrand plan..salbutamol.by himanshu tripathi
Brand plan..salbutamol.by himanshu tripathiHimanshu Tripathi
 
Brand plan for a SPA
Brand plan for a SPABrand plan for a SPA
Brand plan for a SPAarpan9roy
 

Andere mochten auch (20)

Ideal Brand Plan
Ideal Brand PlanIdeal Brand Plan
Ideal Brand Plan
 
Brand Plan Workshop
Brand Plan WorkshopBrand Plan Workshop
Brand Plan Workshop
 
Pharmaceutical Marketing Management
Pharmaceutical Marketing ManagementPharmaceutical Marketing Management
Pharmaceutical Marketing Management
 
Panadol ppt
Panadol pptPanadol ppt
Panadol ppt
 
Pharma Plan Presentation Powerpoint
Pharma Plan Presentation PowerpointPharma Plan Presentation Powerpoint
Pharma Plan Presentation Powerpoint
 
Beloved brands-brand-plan
Beloved brands-brand-planBeloved brands-brand-plan
Beloved brands-brand-plan
 
I've Got Nothing To Tell About My Brand!
I've Got Nothing To Tell About My Brand!I've Got Nothing To Tell About My Brand!
I've Got Nothing To Tell About My Brand!
 
Apresentação vip calçados
Apresentação vip calçadosApresentação vip calçados
Apresentação vip calçados
 
Navicor Corporate Brochure
Navicor Corporate BrochureNavicor Corporate Brochure
Navicor Corporate Brochure
 
The Math Behind Your Blog
The Math Behind Your BlogThe Math Behind Your Blog
The Math Behind Your Blog
 
Csp edp
Csp edpCsp edp
Csp edp
 
Desenvolvendo Plano de Ação 2-10 - Desvendando o Ciclo PDCA
Desenvolvendo Plano de Ação 2-10 - Desvendando o Ciclo PDCADesenvolvendo Plano de Ação 2-10 - Desvendando o Ciclo PDCA
Desenvolvendo Plano de Ação 2-10 - Desvendando o Ciclo PDCA
 
Visual Storytelling-Drive Social Media Engagement
Visual Storytelling-Drive Social Media EngagementVisual Storytelling-Drive Social Media Engagement
Visual Storytelling-Drive Social Media Engagement
 
19 reasons why pharma marketing should start with telling the story of their ...
19 reasons why pharma marketing should start with telling the story of their ...19 reasons why pharma marketing should start with telling the story of their ...
19 reasons why pharma marketing should start with telling the story of their ...
 
Brand strategy executive summary slideshare
Brand strategy executive summary slideshareBrand strategy executive summary slideshare
Brand strategy executive summary slideshare
 
What If Everyone Understood Your Brand Plan?
What If Everyone Understood Your Brand Plan?What If Everyone Understood Your Brand Plan?
What If Everyone Understood Your Brand Plan?
 
Patient profiling disaggregating the data
Patient profiling disaggregating the dataPatient profiling disaggregating the data
Patient profiling disaggregating the data
 
Brand plan..salbutamol.by himanshu tripathi
Brand plan..salbutamol.by himanshu tripathiBrand plan..salbutamol.by himanshu tripathi
Brand plan..salbutamol.by himanshu tripathi
 
Brand plan for a SPA
Brand plan for a SPABrand plan for a SPA
Brand plan for a SPA
 
Ferrero natale
Ferrero nataleFerrero natale
Ferrero natale
 

Ähnlich wie Brand plan for 2010 glycomet (us vitamin) - mitesh shah

IMC Plan for BRAND’S®
IMC Plan for BRAND’S®IMC Plan for BRAND’S®
IMC Plan for BRAND’S®Vincs Kong
 
MSP assigment submit
MSP assigment submitMSP assigment submit
MSP assigment submitOlu Akani
 
¨Presentation Brand and reputation survey2009 f novonordisk
¨Presentation Brand and reputation survey2009 f novonordisk¨Presentation Brand and reputation survey2009 f novonordisk
¨Presentation Brand and reputation survey2009 f novonordiskFethi Ferhane
 
2015/11 - Meet Sanofi Management
2015/11 - Meet Sanofi Management2015/11 - Meet Sanofi Management
2015/11 - Meet Sanofi ManagementSanofi
 
Accure labs presentation
Accure labs presentation Accure labs presentation
Accure labs presentation A.K. Singh
 
Strategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryStrategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryEngr. Carlo Senica, MBA, CPSM
 
Sm Case Jisha & Remya(2)
Sm Case Jisha & Remya(2)Sm Case Jisha & Remya(2)
Sm Case Jisha & Remya(2)guest78d8ca
 
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87cr
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87crHem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87cr
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87crIndiaNotes.com
 
Types And Types Of Diabetes Essay
Types And Types Of Diabetes EssayTypes And Types Of Diabetes Essay
Types And Types Of Diabetes EssaySherry Ferguson
 
International Business in AstraZeneca.docx
International Business in AstraZeneca.docxInternational Business in AstraZeneca.docx
International Business in AstraZeneca.docxwrite4
 
Biocon H1 q2fy10 11
Biocon H1 q2fy10 11Biocon H1 q2fy10 11
Biocon H1 q2fy10 11Biocon
 
johnson n johnson
johnson n johnsonjohnson n johnson
johnson n johnsonanand karki
 
IR Presentation Sept 2015 (USD)
IR Presentation Sept 2015 (USD)IR Presentation Sept 2015 (USD)
IR Presentation Sept 2015 (USD)Elena Ilina
 
Managerial Policy hypothetical project
Managerial Policy hypothetical projectManagerial Policy hypothetical project
Managerial Policy hypothetical projectgohar Iqbal
 
St. Jude Medical 2015 Annual Investor Meeting Presentation
St. Jude Medical 2015 Annual Investor Meeting PresentationSt. Jude Medical 2015 Annual Investor Meeting Presentation
St. Jude Medical 2015 Annual Investor Meeting Presentationir_stjude
 
2015 investor's meeting consolidated slide deck final
2015 investor's meeting consolidated slide deck final2015 investor's meeting consolidated slide deck final
2015 investor's meeting consolidated slide deck finalir_stjude
 

Ähnlich wie Brand plan for 2010 glycomet (us vitamin) - mitesh shah (20)

IMC Plan for BRAND’S®
IMC Plan for BRAND’S®IMC Plan for BRAND’S®
IMC Plan for BRAND’S®
 
MSP assigment submit
MSP assigment submitMSP assigment submit
MSP assigment submit
 
¨Presentation Brand and reputation survey2009 f novonordisk
¨Presentation Brand and reputation survey2009 f novonordisk¨Presentation Brand and reputation survey2009 f novonordisk
¨Presentation Brand and reputation survey2009 f novonordisk
 
Glaxo smith kline
Glaxo smith klineGlaxo smith kline
Glaxo smith kline
 
2015/11 - Meet Sanofi Management
2015/11 - Meet Sanofi Management2015/11 - Meet Sanofi Management
2015/11 - Meet Sanofi Management
 
Accure labs presentation
Accure labs presentation Accure labs presentation
Accure labs presentation
 
Strategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryStrategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical Industry
 
Sm Case Jisha & Remya(2)
Sm Case Jisha & Remya(2)Sm Case Jisha & Remya(2)
Sm Case Jisha & Remya(2)
 
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87cr
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87crHem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87cr
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87cr
 
Asif resume
Asif resumeAsif resume
Asif resume
 
Types And Types Of Diabetes Essay
Types And Types Of Diabetes EssayTypes And Types Of Diabetes Essay
Types And Types Of Diabetes Essay
 
International Business in AstraZeneca.docx
International Business in AstraZeneca.docxInternational Business in AstraZeneca.docx
International Business in AstraZeneca.docx
 
Vmg presentation
Vmg presentationVmg presentation
Vmg presentation
 
Eli lilly and company
Eli lilly and companyEli lilly and company
Eli lilly and company
 
Biocon H1 q2fy10 11
Biocon H1 q2fy10 11Biocon H1 q2fy10 11
Biocon H1 q2fy10 11
 
johnson n johnson
johnson n johnsonjohnson n johnson
johnson n johnson
 
IR Presentation Sept 2015 (USD)
IR Presentation Sept 2015 (USD)IR Presentation Sept 2015 (USD)
IR Presentation Sept 2015 (USD)
 
Managerial Policy hypothetical project
Managerial Policy hypothetical projectManagerial Policy hypothetical project
Managerial Policy hypothetical project
 
St. Jude Medical 2015 Annual Investor Meeting Presentation
St. Jude Medical 2015 Annual Investor Meeting PresentationSt. Jude Medical 2015 Annual Investor Meeting Presentation
St. Jude Medical 2015 Annual Investor Meeting Presentation
 
2015 investor's meeting consolidated slide deck final
2015 investor's meeting consolidated slide deck final2015 investor's meeting consolidated slide deck final
2015 investor's meeting consolidated slide deck final
 

Mehr von Mitesh Shah

Report On Marketing Plan Of Ut Tone
Report On Marketing Plan Of Ut ToneReport On Marketing Plan Of Ut Tone
Report On Marketing Plan Of Ut ToneMitesh Shah
 
Marketing Plan For Ut Tone
Marketing Plan For Ut ToneMarketing Plan For Ut Tone
Marketing Plan For Ut ToneMitesh Shah
 
Report On Market Survey Of Cetrizine As Otc
Report On Market Survey Of Cetrizine As OtcReport On Market Survey Of Cetrizine As Otc
Report On Market Survey Of Cetrizine As OtcMitesh Shah
 
IMC campaign for Revital (Ranbaxy)
IMC campaign for Revital (Ranbaxy)IMC campaign for Revital (Ranbaxy)
IMC campaign for Revital (Ranbaxy)Mitesh Shah
 
IMC campaign for Revital (Ranbaxy)
IMC campaign for Revital (Ranbaxy)IMC campaign for Revital (Ranbaxy)
IMC campaign for Revital (Ranbaxy)Mitesh Shah
 
Market survey on azithromycin and amoxicillin with clavulanic acid
Market survey on azithromycin and amoxicillin with clavulanic acidMarket survey on azithromycin and amoxicillin with clavulanic acid
Market survey on azithromycin and amoxicillin with clavulanic acidMitesh Shah
 
Overview on pharmaceutical industry
Overview on pharmaceutical industryOverview on pharmaceutical industry
Overview on pharmaceutical industryMitesh Shah
 

Mehr von Mitesh Shah (7)

Report On Marketing Plan Of Ut Tone
Report On Marketing Plan Of Ut ToneReport On Marketing Plan Of Ut Tone
Report On Marketing Plan Of Ut Tone
 
Marketing Plan For Ut Tone
Marketing Plan For Ut ToneMarketing Plan For Ut Tone
Marketing Plan For Ut Tone
 
Report On Market Survey Of Cetrizine As Otc
Report On Market Survey Of Cetrizine As OtcReport On Market Survey Of Cetrizine As Otc
Report On Market Survey Of Cetrizine As Otc
 
IMC campaign for Revital (Ranbaxy)
IMC campaign for Revital (Ranbaxy)IMC campaign for Revital (Ranbaxy)
IMC campaign for Revital (Ranbaxy)
 
IMC campaign for Revital (Ranbaxy)
IMC campaign for Revital (Ranbaxy)IMC campaign for Revital (Ranbaxy)
IMC campaign for Revital (Ranbaxy)
 
Market survey on azithromycin and amoxicillin with clavulanic acid
Market survey on azithromycin and amoxicillin with clavulanic acidMarket survey on azithromycin and amoxicillin with clavulanic acid
Market survey on azithromycin and amoxicillin with clavulanic acid
 
Overview on pharmaceutical industry
Overview on pharmaceutical industryOverview on pharmaceutical industry
Overview on pharmaceutical industry
 

Brand plan for 2010 glycomet (us vitamin) - mitesh shah

  • 1. BRAND PLAN FOR 2010 BRAND – GLYCOMET (US VITAMIN) YEAR 2010 PREPARED BY : MITESH SHAH SUBMITTED TO : Mr. PRATIM VORA YEAR 2010
  • 2. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 2 To provide our manager, our peers and our Representatives with a clear and concise review of the primary strategies, the tactics and the performance objectives that we have planned for the upcoming year. The reader of our Executive Summary should be able to answer the following regarding our responsibilities, objectives and measurements for the year: Our annual unit sales and revenue objectives for the year. Our most recent years' performance compared to our projected performance. The primary strategies and tactics that will get us there. Our customer segmentation scheme by history and by forecast. Our rationale for our targeted regions and territories. An overview of sales of our organization. Our anticipated requirements for hiring, training and developing sales personnel. Our measurement criteria.  This should concisely highlight brnd Plan.  This must be appealing, compelling and well organized enough for the reader to obtain a very comprehensive understanding of our entire market and our plan of attack. EXECUTIVE SUMMARY
  • 3. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 3 TABLE OF CONTENT Sl. No. Particular Page No. Company – US Vitamin profile 05  India Operation 05  Therapeutically segments covered in India 05  Business unit 05  Market Standing 06  Marketing capabilities 06  Distribution Network 07  Partners in India 07  Manufacturing facilities 08  Diabetes 08  Market in world 10 Brand – Glycomet Detail 11 Product Design 12 Price 14 Promotional Strategies 15  Effective promotional strategy 15  Pre Launch Activities 15  Post Launch Activities 16 Situational and Competitive Analysis 17 SWOT Analysis 19
  • 4. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 4 Anti Diabetic Drugs – Existing Brands 21  Sales Plan 32  Sales Planning for the sales manager 32   Sales Objectives 33   Hiring Plan 42  Recruiting, Hiring and Training Table 43  Training Requirement 45  Plan our Incentive Package 45  Award Programs 46 Report and Monitor 48
  • 5. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 5 INDIA OPERATIONS  USV total sales for the year 2008-09 were Rs. 6050 million.  USV sales in India contribute to 68% of our total business.  USV rank 23rd in the Indian Pharmaceutical Industry (Source: ORG; April 2009) with leadership positions in several product categories. THERAPEUTIC SEGMENTS COVERED IN INDIA INCLUDE  Diabetes  Cardiovascular  Orthopaedics  Nutritional  Respiratory  Dermatology  Gynaecology  Paediatrics  CNS BUSINESS UNIT  The domestic operations are divided into six business units each with separate infrastructure for sales and marketing. Condor  Focus on Diabetes Corvette  Focus on Cardiology Pharma  Focus on Gynecology, Dermatology, Respiratory and Pediatrics Centra  Focus on Neurology and Psychiatrist Conquer  Focus on Diabetes and Cardiology Cosmeceutical  Focus on Dermatology and Cosmetology COMPANY – USV PROFILE
  • 6. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 6 Market standing  Leader in Diabetes & Cardiology in terms of prescription generation.  Presence in Cosmetology with a leading European brand.  Presence in Nutritionals, Respiratory, Gynecology through innovative products from partners in USA and Europe.  USV lead the oral anti-diabetic segment in India in terms of value as well as prescriptions. USV have maintained a leadership position in this segment for almost two decades.  32% of our sales are contributed by the anti- diabetic portfolio, which includes insulin.  We lead in the cardiovascular disease segment in terms of prescription generation. In terms of value, we rank amongst the first 10 companies in India. The cardiology portfolio contributes 32% to our sales.  Presence in Respiratory, Nutritionals, Orthopedics and Gynecology segments is attributed to innovative products through partnerships with companies from Europe and USA.  We have a significant presence in Dermatology with a leadership position in the anti-acne segment. We have recently launched Sebamed range of skin-care products from Europe.  USV has also ventured into the CNS segment with the launch of a new division to cater the needs of Neurologists and Psychiatrists. MARKETING CAPABILITIES  We have a focused marketing team for every business unit. The emphasis is on brand building:  Rigorous and regular medical and sales training of the field force  Enhancing knowledge about our products and related disease among physicians by organizing Continuing medical education programs  Enhancing detection of undiagnosed diseases through detection camps  Enhancing patients' awareness about diseases by organizing several patient education programs  Ethical promotion of pharmaceutical products  Some examples of our Brand Building Capabilities  We are the 3rd largest by prescription for calcium product  Our products have leadership positions in anti-oral diabetic, anti-coagulant and multivitamin (without minerals) markets  Our focused marketing capabilities and ethical promotion of scientific products resulted in establishing premium brands
  • 7. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 7 DISTRIBUTION NETWORK  A 1300 strong sales team works to provide essential product information to over 150,000 Physicians and the distribution network of 1,270 stockiest and 55,000 retailers has the volume handling capability to deliver products to markets in the fastest possible time.  Central Warehouse  22 Clearing & Forwarding (C&F) Agents  1270 Distributors  55,000 Retailers  Cold Chain capability PARTNERS IN INDIA Company Product Therapeutic category Year of partnership Novartis, India Vildagliptin Diabetes 2008 Roche Xenical Anti-Obesity 2008 Sebapharma, Germany Sebamed Cosmeceuticals 2006 Fujix Inc., Japan TripleACal Nutritional 2004 Kissei, Japan Kissei, Japan Diabetes 2006 Engelhard, Germany Prospan Respiratory 2005 Alfa Wassermann, Italy Fluxum Cardiology 1994 Cimab IORT3 Nephrology 1994 OM Pharma, Switzerland Broncho- Munal Respiratory 2005
  • 8. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 8 MANUFACTURING FACILITIES  US & EU approved solid oral dosages facility  The EU approved plant for tablets, coated tablets and capsules is state-of-the-art. Built to cGMP standards and ICH guidelines, it is designed for unidirectional flow of material.  The plant offers 6 packaging options including Blister, Strip, Alu-Alu, Pouch, Bottle packaging and Bulk packaging. Bottle packaging will be available shortly.  Some highlights of this plant include centralized automated control systems that detect minor variations in air and temperature levels in sterile zones, building maintenance and water facilities that conform to international standards, and back-up systems that ensure minimal downtime.  Salient features  Tablets, coated tablets and capsules.  Built to cGMP standards and ICH guidelines.  WHO-GMP approved.  Single shift capacity o Tablets 3 billion o Capsules 1.5 billion.  Approved by National Health Authority of Finland.  New inject able facility validated by US FDA  DIABETES  The global prevalence of Diabetes is estimated to increase from 4% in 1995 to 5.4% by the year 2025.  Diabetes is steadily assuming epidemic proportions globally. As per IDF Atlas 2003, a 62% increase in incidence of Diabetes is expected by year 2025.  Incidence of Diabetes is no longer restricted to the US & Europe.  In fact, maximal increase in the incidence of Diabetes is observed in the Developing world. This is corroborated by the following observations: Continent Year 2003 Year 2025 % Incidence Estimates Change SE Asia 39.3 81.6 108 Rest Asia + Aust. 43.0 75.8 76 Africa 7.1 15.0 111 Latin America 14.2 26.2 85  Family history of Diabetes, Age, Body Mass Index (BMI), waist to hip ratio and a sedentary life-style showed positive association with diabetes in Indian population.
  • 9. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 9  Our existing Brands for Diabetic Treatments o Duotrol o Glizide o Glyboral o Glycomet o Glycomet SR o Glynase o Glynase MF o Glynase XL o GP 1 & 2 o Pioz
  • 10. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 10 MARKET IN WORLD  Sri Lanka  USV ranks 13th among pharmaceutical companies in this market.  5 brands feature among the top 30 brands (IMS Dec. 08)  In the OHA segment Metformin and Pioglitazone are leaders.  In the Cardiovascular disease also USV is leading company.  Myanmar  We have a strong presence in the Nutritionals, Cardiovascular & Anti-Diabetes segments through promotion of our products by an active and aggressive field force. Our Multivitamins, Piolitazone and Fenofibrate are leaders in their respective segments. Cambodia  Our approach in Cambodia is to create an awareness for and acceptance of Chronic Care segments, that is, Diabetes and Cardiovascular diseases. We have a strong presence in Multivitamin and Pain Management segments. Our focus is on brand building through an aggressive sales team and strong distribution. Singapore  USV has a strong presence in the diabetes segment in the Diabetes segment. Glycomet the star product is available in many hospitals through tenders. AFRICA  USV present Uganda, Sudan and Kenya. A blend of Cardiology and Anti-diabetes products along with select Nutritionals are promoted in these countries by Distributors.  USV will soon be launching products in the Francophone region with business commencing in Benin, Cameroon, Ivory Coast, Niger and Burkina Faso. CIS  USV operates in Kazakhstan and Ukraine through its own field force, working towards building strong brand equity with leading Endocrinologists and Cardiogolists. USV also a presence in the Nutritionals and Pain Management segments in these markets.
  • 11. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 11 Glycomet Ingredients Each tablet contains metformin 500mg, 850mg, 1000mg Category Anti-hyperglycemic, insulin sensitizer Indications  Obese/non obese type 2 diabetes mellitus, as a monotherapy or in combination with sulfonlyureas, thiazolidinediones and insulin  It is also used in type 1 diabetes along with insulin  Polycystic ovarian syndrome Dosage 1/2 tablet to 2 tablets once daily to be taken before or after meals. Disclaimer Products under patents are offered for sale only in those countries where patents have expired. The FDA approved this medication in December, 1994 Countries Trade Name of Glycomet USA Glucophage, glucophage xr, glumetza Canada Apo-metformin, gen-metformin, glucophage, glycon, novo-metformin, nu-metformin Mexico Dabex, dimefor, glucophage Other Countries Gluformin l, gluformin, bigesens, bigomet, cetapin, diaformin, diamet, dibeta-sr, dibimet, e met, emfor, zetfor, zomet, glyciphage, glycomet. BRAND – GLYCOMET DETAIL
  • 12. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 12 GLYCOMET (metformin hydrochloride) Tablets 500 mg Bottles of 100 500 mg Bottles of 500 850 mg Bottles of 100 1000 mg Bottles of 100 GLYCOMET 500 mg tablets  Round  White to off-white  Film-coated tablets debussed with “BMS 6060” around the periphery of the tablet on one side  “500” debussed across the face of the other side GLYCOMET 850 mg tablets  Round  White to off-white  Film-coated tablets debussed with “BMS 6070” around the periphery of the tablet on one side  “850” debussed across the face of the other side. GLYCOMET 1000 mg tablets  White  Oval  Biconvex  Film-coated tablets with “BMS 6071” debussed on one side and “1000” debussed on the opposite side PRODUCT DESIGN
  • 13. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 13  A bisect line on both sides GLYCOMET XR (metformin hydrochloride) Extended-Release Tablets 500 mg Bottles of 100 750 mg Bottles of 100 GLYCOMET XR 500 mg tablets  White to off-white  Capsule shaped  Biconvex tablets  “BMS 6063” debussed on one side  “500” debussed across the face of the other side GLYCOMET XR 750 mg tablets  Capsule shaped  Biconvex tablets  “BMS 6064” debussed on one side  “750” debussed on the other side  The tablets are pale red and may have a mottled appearance
  • 14. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 14 Product Price Quantity Glycomet 500mg Rs. 12.22 10 Tablets Glycomet 850mg Rs. 16.40 10 Tablets Glycomet 1000mg Rs. 32 10 Tablets Glycomet XR 500mg Rs. 20.24 10 Tablets Glycomet XR 750mg Rs. 32 10 Tablets PRICE
  • 15. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 15 Effective Promotional Strategy  Advertising media  Print media (newspaper, magazine, classified ads, brochure)  Networking  Business cards  Tee shirts, hats, buttons, pens  Printed promotional material  Audio-visual and computer-based promotional material  Develop a promotional strategy that uses various media for promoting our brand. Monitor the different media identifying those that most effectively promote our brand. Concentrate on developing material for these formats that clearly identifies our brand. PRE LAUNCH ACTIVITIES  The target audience for the horizon scanning and planning information includes:  NHS(National Health Service) Commissioners  Formulary or directorate pharmacists  PCT(Primary care trust) pharmacists  Senior pharmacy managers  Directors of Public Health  Finance directors  Chief executives  National Horizon Scanning Centre  Department of Health  NICE implementation leads  The target audience for New Medicines Profiles and Therapeutic Class Summaries is: Medicines information pharmacists  Formulary or directorate pharmacists  PCT pharmacists  Senior pharmacy managers  Prescribers from primary and secondary care Prescribing committees PROMOTIONAL STRATEGY
  • 16. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 16 POST LAUNCH ACTIVITIES  Time to market: Worst enemy of the regulator  Reducing uncertainties that preexist when drugs are taken into the market (long term outcomes, efficacy/safety in some populations)  Commitments: which data should be collected post launch?  Grey zone, not specifically regulated, unclear ownership and funding  Need for stakeholder collaboration  Need for incentives: case of personalized (stratified) medicine
  • 17. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 17 Situational Analysis  Some of the factors to be considered in conducting a situational analysis are:  The economic structure of the India and its individual communities  Topographical and other physical characteristics of the India  Governmental, public, private, community, and other support systems available  Characteristics of the population, including: o Educational levels o Cultural characteristics o Life styles and living standards o Primary occupations o Income levels o Communities and their distinguishing characteristics o Mobility and rates on inflow and outflow of citizens o Any other aspect of society that may be useful in assessing factors such as attitudes, motivation, and other characteristics of individual learner groups.  A useful tool in performing a Situation Analysis is what we might call The C's of Marketing. The C's of marketing help companies focus on key elements that apply directly to marketing. The 5 C's of Marketing can be summarized as:  Company  The product time line, experience in the market, etc.  Collaborators  Distributors, suppliers, and alliances. These are for companies that you work with on a day to day basis to help company run.  Customers  This is our market. Ask yourself what benefits they are looking for. Where the customer does actually purchases your product? How the product is purchased (internet, etc)? Understand the quantity a customer will purchase and even trends in consumer tastes. SITUATIONAL & COMPETITIVE ANALYSIS
  • 18. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 18  Competitors  Both our actual and potential competitors and those that directly or indirectly compete with us. Understand our products, positioning, market shares, strengths and weaknesses.  Climate (or Environment)  These are governmental policies and regulations that affect the market. It is also the economic environment around our company; which is the business cycle, inflation rate, interest rates, and other macroeconomic issues. Society's trends and fashions are found in the "climate." Important Factors to Consider in Competitive Analysis  Define target market.  Determine the size of the target market.  Drill down to specific segment within the target market.  Define the size and the revenue opportunity that segment represents.  Determine how fast the overall market and specific segment are growing.  Identify your direct and indirect competitors and understand their impact on you.  Identify the features that differentiate your product from the competitors.
  • 19. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 19 Strengths  Low cost of production  Large pool of installed capacities  Efficient technologies for large number of Generics.  Large pool of skilled technical manpower  Increasing liberalization of government policies Opportunities  Aging of the world population  Growing incomes  Growing attention for health  Saturation point of market is far away  New therapy approaches  New delivery systems  Globalization  Easier international trading  New markets are opening Weakness  Fragmentation of installed capacities  Low technology level of Capital Goods of this section  Non-availability of major intermediaries for bulk drugs  Lack of experience to exploit efficiently the new patent regime  Low key R&D  Low level of strategic planning for future and also for technology forecasting Threats  Containment of rising health-care cost  Stricter registration procedures  High entry cost in newer markets  High cost of sales and marketing  Competition, particularly from generic products  More potential new drugs and more efficient therapies  Switching over form process patent to product patent  Drug Price Control Organization (DPCO) SWOT ANALYSIS
  • 20. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 20 To create a brand promise, it should be:  Grounded in the brand’s core values  Clearly relevant and engaging to our target market  Repeated internally and externally within our organization  Adaptable to the climate  Continually reinforced  Consistent across advertising and marketing mediums
  • 21. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 21 ANTI DIABETIC DRUGS INGREDIENT NAME MARKET NAME COMPANY NAME QUANTITY PACKING PREPARATION OF METFORMIN BIGESENS ZYDUS CADILA 500MG 10 TAB XR 1GM 10 TAB XR BIGOMET OTSIRA GENETICA 250MG 10TAB 500MG 10TAB 850MG 10TAB 500MG 10 TAB SR 1000MG 10 TAB SR CETAPIN AVENTIS 500MG 10TAB D-BAY ARGUS 500MG 10TAB 850MG 10TAB DAOMET JB CHEMICAL 500MG 10 TAB SR 100MG 10 TAB SR DIAFORMIN CFL 500MG 10TAB DIAMET BAL PHARMA 500MG 10TAB 850MG 10TAB 500MG 10 TAB SR 1000MG 10 TAB SR DIBETA-SR 500 TORRENT 500MG 10 TAB SR 1GM 10 TAB SR DIBIMET NOVARTIS 500MG 10TAB EMET ELEGANT DRUGS 500MG 10TAB EMFOR STADMED 500MG 10TAB ANTI DIABETIC DRUGS – EXISTING BRANDS (SOURCE – INDIAN DRUG RECORD)
  • 22. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 22 EMNORM IPCA 250MG 10TAB 500MG 10TAB 850MG 10TAB ETFORMIN DEYS 500MG 10TAB FORMET CHEMECH LABS 500MG 10TAB 1GM 10 TAB SR FORMIN ALKEM 500MG 10TAB 850MG 15 TAB FORMIN-500 STATMED 500MG 10TAB FORMINAL ALEMBIC 500MG 10TAB 850MG 10TAB GLUFORMIN NPIL 500MG 10TAB 850MG 10TAB GLUFORMIN XL NPIL 500MG 10 TAB XR 1000MG 10 TAB XR GLUMET PROTEC 500MG 10TAB 850MG 10TAB GLUMET-XR PROTEC 500MG 10 TAB XR GLYCIPHAGE FRANCO INDIAN 250MG 10TAB 500MG 10TAB 850MG 10TAB 500MG 10 TAB SR GLYCOMET USV 500MG 10TAB 850MG 10TAB 1GM 10 TAB SR GLYREP EMCURE 500MG 10TAB 1GM 10TAB INSUMET CADILA PHARMA 500MG 10TAB 850MG 10TAB 500MG 10 TAB SR MELMET MICRO LABS 500MG 10TAB METCHEK RADIUS 500MG 10TAB 850MG 10TAB
  • 23. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 23 METCOM COMED 500MG 10TAB 850MG 10TAB METLONG PANACEA 500MG 10TAB METMIN JENBURKT 500MG 10 TAB MF-SR PIL 500MG 10 TAB SR 1GM 10 TAB SR RIOMET OD RANBAXY CV 500MG 10TAB 1GM 10TAB WALAPHAGE WALLACE 500MG 10 TAB 850MG 10 TAB XMET HEALTHEON 250MG 10 TAB 500MG 10 TAB 850MG 10 TAB ZETFOR RAPTAKOS 500MG 10 TAB 850MG 10 TAB 500MG 10 TAB CR ZOMET INTAS 500MG 10 TAB 850MG 10 TAB 500MG 10 TAB SR 1000MG 10 TAB SR COMBINATION OF METFORMIN & GLIBENCLAMIDE BENCLAMET RPG LIFE SCIENCE METFORMIN 400MG 10 TAB GLIBENCLAMID E 2.5MG BENCLAMET FORTE RPG LIFE SCIENCE METFORMIN 500MG 10 TAB GLIBENCLAMID E 5MG DIABETROL NPIL METFORMIN 500MG 10 TAB GLIBENCLAMID E 5MG DUOTOROL USV METFORMIN 500MG 10 TAB GLBENCLAMIDE 5MG GLIBOMET MENARINI RAUNAQ METFORMIN HCL 400MG 10 TAB
  • 24. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 24 GLIBENCLAMID E 2.5MG GLIBOMET FORT MENARINI RAUNAQ METFORMIN HCL 500MG 10 TAB FORTE GLIBENCLAMID E 5MG GLUCONIL-M BAL PHARMA METFORMIN HCL 500MG 10 TAB GLIBENCLAMID E 5MG GLUCORED SUN PHARMA METFORMIN 400MG 10 TAB GLIBENCLAMID E 2.5MG METFORMIN 500MG 10 TAB FORTE GLIBENCLAMID E 5MG GLUCOTRAC INTRA LABS METFORMIN 400MG 10 TAB GLIBENCLAMID E 2.5MG GLUCOTRAC PLUS INTRA LABS METFORMIN 500MG 10 TAB GLIBENCLAMID E 5MG GLYCURB / FORT WIN MEDICARE METFORMIN 400MG 8*7 TAB GLIBENCLAMID E 2.5MG METFORMIN 500MG 8*7 TAB GLIBENCLAMID E 5MG MELITUS NPIL METFORMIN 400MG 10 TAB GLIBENCLAMID E 2.5MG SUGATROL ARGUS METFORMIN 400MG 10 TAB GLIBENCLAMID E 2.5MG COMBINTION OF METFORMIN & GLIPIZIDE BIMODE-M NUCRON PHARMA METFORMIN 400MG 10 TAB GLIPIZIDE 2.5MG DIACON-M BAL PHARMA METFORMIN 500MG 10 TAB
  • 25. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 25 GLIPIZIDE 5MG DIACON-M BAL PHARMA METFORMIN 500MG 10 TAB GLIPIZIDE 5MG GLIMET DS FRANCO INDIAN METFORMIN 250MG 10 TAB GLIPIZIDE 2.5MG GLIPIMET AZTEC METFORMIN 400MG 10 TAB GLIPIZIDE 2.5MG GLUCOTROL-MF JENBURKT METFORMIN HCL 500MG 10 TAB GLIPIZIDE 5MG GLYNASE MF USV METFORMIN 500MG 10 TAB GLIPIZIDE 5MG LIPI-M DEYS METFORMIN 500MG 10 TAB GLIPIZIDE 5MG METAGLEZ/FORT E OTSIRA GENETICA METFORMIN HCL 400MG 10 TAB GLIPIZIDE 2.5MG METGLIB-500 TAURUS LABS METFORMIN 500MG 10 TAB GLIPIZIDE 5MG TRANASE-MF INTRA LABS METFORMIN 500MG 10 TAB GLIPIZIDE 5MG ZIDMIN TRIDOSS METFORMIN 500MG 10 TAB GLIPIZIDE 5MG COMBINATION OF METFORMIN & GLICLAZIDE AZUKON-M TORRENT METFORMIN 500MG 10 TAB GLICAZIDE 80MG COMZID-M COMED METFORMIN HCL 500MG 10 TAB GLICAZIDE 80MG DIABEND-M BAL PHARMA METFORMIN 10 TAB
  • 26. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 26 500MG GLICAZIDE 80MG DIANORM-M CARSYON METFORMIN 500MG 10 TAB GLICAZIDE 80MG DIATROL-M ARGUS METFORMIN 5OOMG 10 TAB GLICAZIDE 80MG EUCLIDE-M ALKEM METFORMIN 500MG 10 TAB GLICAZIDE 80MG GLICAMET BIOCHEM METFORMIN HCL 500MG 10 TAB GLICAZIDE 80MG GLICLAZ-M KHANDELWAL METFORMIN 500MG 10 TAB GLICAZIDE 80MG GLIDIET-M MODI-MUNDI PHARMA METFORMIN 500MG 10 TAB GLICAZIDE 80MG GLIDIET-M WIN MEDICARE METFORMIN 500MG 10 TAB GLICAZIDE 80MG GLIZA-MF STADMED METFORMIN HCL 500MG 10 TAB GLICAZIDE 80MG GLIZID-M PANACEA METFORMIN 500MG 10 TAB GLICAZIDE 80MG GLUCOFIT-M RAPTAKOS METFORMIN HCL 500MG 10 TAB GLICAZIDE 80MG GLUCOZID-M MEDLEY PHARMA METFORMIN HCL 500MG 10 TAB GLICAZIDE 80MG GLYCHEK-M INDOCO METFORMIN HCL 500MG 10 TAB
  • 27. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 27 GLICAZIDE 80MG GLYCIGON-M ARISTO METFORMIN 500MG 10 TAB GLICAZIDE 80MG GLYCINORM-M 8OMG IPCA METFORMIN 500MG 10 TAB GLICAZIDE 80MG GLYGARD-M CIPLA METFORMIN HCL 500MG 10 TAB GLICAZIDE 80MG GLYKIND-M MANKIND PHARMA METFORMIN 500MG 10 TAB GLICAZIDE 80MG GLYLOC-M CADILA PHARMA METFORMIN HCL 500MG 10 TAB GLICAZIDE 80MG GLERED-M NOVARTIS METFORMIN HCL 500MG 10 TAB GLICAZIDE 80MG GLZ PLUS ALEMBIC METFORMIN 500MG 10 TAB GLICAZIDE 80MG LIZ-M DEY'S METFORMIN 500MG 6 TAB GLICAZIDE 80MG LYCAZID-M JAGSONPAL METFORMIN HCL 500MG 1O TAB GLICAZIDE 80MG MINTIDE VENUS REMEDIES METFORMIN HCL 500MG 10 TAB GLICAZIDE 80MG NUZIDE-M INTAS METFORMIN 500MG 1O TAB GLICAZIDE 80MG RECLIMET DR. REDDY'S LAB METFORMIN 500MG 10 TAB GLICAZIDE 80MG
  • 28. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 28 WALFORMIN WALLACE METFORMIN HCL 500MG 10 TAB GLICAZIDE 80MG ZYDE-MF PIL METFORMIN HCL 500MG 10 TAB GLICAZIDE 80MG COMBINATION OF METFORMIN WITH GLIMEPRIDE AZULIX 1/2 MF NOVARTIS METFORMIN 500MG 10 TAB GLIMEPRIDE 1MG AZULIX 1/2 MF FORTE TORRENT METFORMIN 1000MG 10 TAB GLIMEPRIDE 1MG BETAGRIM-M PANACEA METFORMIN 500MG 10 TAB GLIMEPRIDE 1MG DAORYL-M JB CHEMICAL METFORMIN BI LAYERED TABLET 10 TAB GLIMEPRIDE 1MG EUGLIM-M-1/2 ZYDUS CADILA METFORMIN 500MG 10 TAB GLIMEPRIDE 1MG GLIMIPREX-MF (SUSTAIN RELEASE) OTSIRA GENETICA METFORMIN 500MG 10 TAB GLIMEPRIDE 1MG GLIMPIL-MF (SR) PIL METFORMIN 500MG 10 TAB GLIMEPRIDE 1MG GLISTA M1/M2 (SR) CADILA PHARMA METFORMIN 500MG 10 TAB GLIMEPRIDE 1MG GLM (SR) SYSTOPIC METFORMIN 500MG 10 TAB GLIMEPRIDE 1MG
  • 29. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 29 GLUFORMIN G1/G2-SR NPIL METFORMIN 500MG 10 TAB GLIMEPRIDE 1MG GMT-SR INDOCO METFORMIN 500MG 10 TAB GLIMEPRIDE 1MG METRIDE-SR UNISEARCH METFORMIN 500MG 10 TAB GLIMEPRIDE 1MG METRIDE PLUS UNISEARCH METFORMIN 500MG 10 TAB GLIMEPRIDE 1MG PIOGLITAZONE 15MG PRICHEK-M INDOCO METFORMIN 500MG 10 TAB GLIMEPRIDE 1MG ZORYL M - SR INTAS METFORMIN 500MG 10 TAB GLIMEPRIDE 1MG COMBINATION OF METFORMIN WITH ROSIGLITAZONE ENSELIN 2MF TORRENT METFORMIN 500MG 10 TAB ROSIGLITAZONE 2MG ENSELIN-4MF TORRENT METFORMIN 500MG 10 TAB ROSIGLITAZONE 4MG ENSELIN 2MF FORTE TORRENT METFORMIN 1000MG 10 TAB ROSIGLITAZONE 2MG ENSELIN 4MF FORTE TORRENT METFORMIN 1000MG 10 TAB ROSIGLITAZONE 4MG REZULT-M AZTEC(SUN) METFORMIN 500MG 10 TAB ROSIGLITAZONE 2MG
  • 30. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 30 REZULT M4 AZTEC(SUN) METFORMIN 500MG 10 TAB ROSIGLITAZONE 4MG ROGLIN-M2 ARISTO METFORMIN 500MG 10 TAB ROSIGLITAZONE 2MG ROGLIN-M4 ARISTO METFORMIN 500MG 10 TAB ROSIGLITAZONE 4MG ROSICON-MF HEALTHEON METFORMIN 500MG 10 TAB ROSIGLITAZONE 2MG ROSIMET PANACEA METFORMIN 500MG 10 TAB ROSIGLITAZONE 2MG ROSINORM-M MICRO LABS METFORMIN 500MG 10 TAB ROSIGLITAZONE 2MG ROSIZON-MT EMCURE METFORMIN 500MG 10 TAB ROSIGLITAZONE 4MG COMBINATION OF METFORMIN WITH PIOGLITAZONE G-TASE M-ER UNISEARCH METFORMIN 500MG 10 TAB PIOGLITAZONE 15MG GLITA-M-CR STADMED METFORMIN 500MG 10 TAB PIOGLITAZONE 15MG GLIZONE M 15/30 ZYDUS CADILA METFORMIN 500MG 10 TAB PIOGLITAZONE 15MG PIANORM-M-CR CARSYON METFORMIN 500MG 10 TAB PIOGLITAZONE 15MG PIOGLAR-M STANCARE METFORMIN 500MG 10 TAB
  • 31. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 31 PIOGLITAZONE 30MG PIOGLIT-MF SUN PHARMA METFORMIN 500MG 10 TAB PIOGLITAZONE 7.5MG PIOKAP MF KAPL METFORMIN 500MG 10 TAB PIOGLITAZONE 15MG PIOGLU-M EMCURE METFORMIN 500MG 10 TAB PIOGLITAZONE 30MG PIOLET M SR INTAS METFORMIN 500MG 10 TAB PIOGLITAZONE 15MG PIOSAFE-MF SR OTSIRA GENETICS METFORMIN 500MG 10 TAB PIOGLITAZONE 15MG PIOZONE M NPIL METFORMIN 500MG 10 TAB PIOGLITAZONE 15MG PIOZULIN M15 SR CADILA PHAARMA METFORMIN 500MG 10 TAB PIOGLITAZONE 15MG PIOZULIN M30 SR CADILA PHAARMA METFORMIN 500MG 10 TAB PIOGLITAZONE 30MG PIZORAD-MSR RADIUS METFORMIN 500MG 10 TAB PIOGLITAZONE 15MG
  • 32. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 32 SALES PLANNING FOR THE SALES MANAGER  Following steps are required for building a Winning Sales Plan  Summarize our Objectives  Identify the Strategic Objectives  Assess Prior Sales Performance  Segment our Customers  Set This Year's Objectives  Develop Territories Action Plans  Develop Key Accounts Plans  Measure and Monitoring Results  Establish our Annual Sales Planning Cycle  Write the Executive Summary  There are three primary sections to the Sales Plan:  Understand our Sales Objectives  Develop our Action Plans o Rep Territory Plans o Rep Key Account Plans  Measure and Report our Results  The next page outlines how the Sales Plan that we will develop fits into the overall planning requirements of the business. SALES PLAN
  • 33. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 33 Understand our Sales Objectives  Identify the Sales objectives:  To present an overview of our brand's sales objectives as they are defined in our objectives.  This introductory section of our Sales Plan requires us to identify the specific overall sales objectives as reflected in the annual plan. The purpose of this exercise is to ensure that we clearly understand the sales requirements of the brand plan on a quarterly basis and the company's overall brand planning objectives.  The template that is on the next page is a generic table that should be modified and filled in to reflect the specific definitions of our own products. This particular template defines the quarterly sales objectives for products in terms of sales revenue, units and market share. In fact, we may have just one product and additional objectives that we monitor.  Objectives:  Modify this template to fit our own requirements and fill in the Sales Revenue numbers, the unit Sales numbers and the market share percentages by quarter.
  • 34. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 34 Category Q1 Q2 Q3 Q4 Total Total Sales(Rs) Sales of Glycomet 500mg Unit Sales of Glycomet 500mg Sales of Glycomet 850mg Unit Sales of Glycomet 850mg Sales of Glycomet 1000mg Unit Sales of Glycomet 1000mg Sales of Glycomet XR 500mg Unit Sales of Glycomet XR 500mg Sales of Glycomet XR 750mg Unit Sales of Glycomet XR 750mg Market Share of Glycomet 500mg % % % % % Market Share of Glycomet 850mg % % % % % Market Share of Glycomet 1000mg % % % % % Market Share of Glycomet XR 500mg % % % % % Market Share of Glycomet XR 750mg % % % % % Summarize the existing sales performance  Objective of this section is to present the sales data that identifies...  The historical sales performance during the past one to three years depending on the specific performance criteria, and...  The current sales performance.  The intent of this section is to help understand the current perspective of the sales and market share performance of the company.
  • 35. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 35  The information displayed in below graphs should set the stage that will enable us to set this year's objectives.  Outlined below are specific sales performance templates of graphs and tables that should be modified to reflect our own products and the types of objectives that we report. Total Net Sales: 5 years history / this year's BUSINESS PLAN  The first graph outlines total net sales (in this example by Rs) for the prior five years with the current BRAND PLAN projection of sales for 2010-2011.  Having displayed in the prior graph a baseline of historical annual performance and compared this to this year's BRAND PLAN objective, this next graph would display the prior year's sales performance by quarter compared to the sales plan objectives.  The use of this data is to graphically show us how the sales results have trended during the prior year and provide us with a guideline for setting our quarterly objectives for this upcoming year. 2005 2006 2007 2008 2009 2010 7.5 8 10.3 11 13 7 9 10 13 15 25 Total Net Sales By Year: Actual to Plan Actual Sale(Rs. In Cr) Plan Sale (Rs. In Cr)
  • 36. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 36  Market Share Graphs:  These graphs quickly display the positioning of our products compared to those of our competitors. Again, this information provides us with an historical baseline enabling us to more productively create our own objectives for this upcoming year.  Market Share Trend  This first displays an easy-to-read bar graph of market share growth over the period of the prior four years. 2009 Q1 2009 Q2 2009 Q3 2009 Q4 1.5 2.5 4 5 2.5 3 4 5.5 Sales Result For Prior Year By Quarter Compared To Plan Actual Sales(Rs. In Cr) Plan Sales (Rs. In Cr)
  • 37. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 37 Develop our Actions Plans  We will establish the objectives, the tactics and the primary action plans that will be used by us and by our Sales Representatives during the entire year. It is also in this section that we will work with our Sales Representatives to create their Territory Plans and their Key Account Plans. Segment our Customers  Segmentation Tiers  Objective of this is to present specific examples of customer segmentations as they relate to... o The numbers of target customers in each tier, and o The number of end users in each tier.  Segmentation by customer classifications should be used as a tool for us to... o Plan the specific type of sales tactics that we will use for each tier. o Determine the sales call frequency patterns that will be applied to each tier.  We should modify our own customer segmentation depending on... o The overall number of customers in our territory, and 2006 2007 2008 2009 2 4 6 7 6 5 8 10 5 5.5 7 8 8 10.3 11 13 Market Share Trend Over 4 Prior Years Zydus Cadila (Bigesens) Aventis (Cetapin) Novartis (Dibimet) USV (Glycomet)
  • 38. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 38 o The level of the complexity of the sale process, and o The maturity of our products in our markets. Create our Reach & Frequency Objectives  Objective of this is to present the monthly sales call frequency patterns that are expected of our Sales Representatives. Set This Year's Objectives  Objective of this section is to define the specific annual sales objectives in a clear and easy-to-understand manner which is both highly quantifiable and qualitative. Revenue and Market Share Objectives: J F M Q1 A M J Q2 J A S Q3 O N D Q4 Total Total Sales Sales in Rs of Glycomet 500 mg Sales Unit of Glycomet 500mg Tiers Number of physician's Number of calls per month Priority 1 2 3 4 Totals
  • 39. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 39 Sales in Rs of Glycomet 850 mg Sales Unit of Glycomet 850mg Sales in Rs of Glycomet 1000 mg Sales Unit of Glycomet 1000mg Sales in Rs of Glycomet XR 500 mg Sales Unit of Glycomet XR 500mg Sales in Rs of Glycomet XR 750 mg Sales Unit of Glycomet XR 750mg Market share of Glycomet 500mg Market share of Glycomet 850mg
  • 40. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 40 Market share of Glycomet 1000mg Market share of Glycomet XR 500mg Market share of Glycomet XR 750mg Set our End User Objectives  Objective of this is to define the specific monthly and quarterly end user objectives in a clear and easy-to-understand manner which is highly quantifiable. One of these tables should be completed for each product.  In the table shown below, the term, "Baseline" has been used to define the total end user population that we are beginning with."New" end users refer to the number of end users who have not previously been on any therapy. "Switched" end users refer to those end users that have transitioned from a competitor's product. J F M Q1 A M J Q2 J A S Q3 O N D Q4 Total End Users Base Line New Switches Total Set our Customer Objectives  Objective of this is to define the specific monthly and quarterly customer objectives in a clear and easy-to-understand manner which is highly quantifiable. One of these tables should be completed for each product.  In the table shown below, the term, "Baseline" has been used to define the total customer population that we are beginning with. "New “customers refer to the number of customers added each month. "Lost” customers refer to those customers that have transitioned from our product to a competitor's product.
  • 41. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 41 J F M Q1 A M J Q2 J A S Q3 Oct N D Q4 Total Customer Base Line New Lost Total Plan our Sales Force Structure  Objective of this is to define the critical objectives as they relate to the hiring, training and development of our Sales Manager, and our Sales Representatives. Organizational Structure  Objective of this is to graphically show the planned organizational structure for this year.  Shown below is a simple table of a structure that is currently being employed at a business unit level. Plan of Hiring Timetable  Objective of this is to identify...  When the hiring process will begin, and  When the position will be filled, and  When the training will take place, and  The timing for revenue impact in the territory. Hiring Plan  The following is a table of a hiring plan that should be developed over the period of our brand Plan.  We should identify in the table below the quarter in which we must have in place any new hires that are required to make our plan successful.  The purpose of this table is to create a visual map of our hiring plan for the entire year.  The next step in this process is for us to develop a detailed recruiting and training timetable that will provide the back up for these dates.
  • 42. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 42 Hiring Table Positions Q1 Q2 Q3 Q4 Total List any manager positions List the specific rep territories (number of people) List any staff positions Recruiting, Hiring and Training Table  Now that we have defined the quarterly timetable for our expansion or for our replacement hires during the year, we need to fill in the monthly table below with the various components of the hiring process to ensure our hiring objectives, and therefore, our sales objectives will be met.
  • 43. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 43 Recruiting, Hiring and Training Table Category Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Profile Position Confirm approval Hire Recruiter Screening Interviewing Training Internal Training Field Monitor performance Fully Productive Review performance Plan our Training Needs and Requirements:  This details the training requirements for the following categories...  All new sales and marketing hires.  Developmental management training and education for our sales and marketing Manager.  Developmental sales and marketing skills training for our existing Representatives.  Developmental clinical training for our existing Representatives.  Other than the training for new hires, this training should be based on the job requirements of the various positions and our assessment of our current Representatives that some of them may not adequately fill those requirements. This inability may be due to a lack of experience or exposure or training.
  • 44. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 44  Questions to be asked:  Is there any product related information that my sales force or I require to exceed our objectives?  Is there any company related information that my sales force must know to remain well informed?  Is there any new competitive information my sales force needs that will assist them in exceeding our objectives?  Are there any areas of weakness in sales skills, clinical knowledge, territory knowledge or account management skills that can be taught or reinforced through training?  Are there skills that I need to improve my capabilities of sales management? Total Number of customers within territory Number of target customers as a percentage of total % Coverage of target customers (YTD) % Number of accounts in territory % Number of target accounts as a percentage of total % Daily Call Average Training Requirements Training Requirements Category Jan Feb Mar Apr May Jun July Aug Sep Oct Nov Dec Sales Manager Development of Education Management Skills Training New Hires
  • 45. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 45 New Hire Training Current Reps Product Training Clinical Training Sales Skills Training Plan our Incentive Packages  This outlines the primary components of our annual incentive planning for our Representatives. Sales Representatives Incentive Planning  Before we begin to detail our incentive plan, we need to answer the following questions in as much detail as possible in order to ensure clarity not only for we but also for our Representatives and any other associated departments, such as Personnel and Finance, who will review and work with our incentive plan.  Answers to the following questions should be filled in as part of our Sales Plan.  The questions that should be answered here are similar to those above for the following...  What are the Objectives of our Incentive Plan?  What are the Measurements?  What are the Criteria that will be used?  What is the Time Frame?  What is the Pawet Table?  What is the Eligibility? Awards Programs  In addition to the annual incentive plan we have detailed above, the purpose of this section is to identify the primary incentive and award programs that will occur during the year and their proposed timetable. These may be specific incentive
  • 46. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 46 programs that are annual or quarterly, or award programs that will be given at national sales meetings.  Examples are: Sales Rep of the Year, Sales Rookie of the Year, and Council of Excellence. Incentive Program Description Territories Month Opportunity Segments What are the Opportunities? What are the Primary Tactics? Obj. Tactics or Action Items Budget or Resources Required Return on Investment Criteria Month to be Completed 1. 2. 3. 4. 5.
  • 47. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 47 Report & Monitor  This section details the monthly reporting requirements. Recommended Monthly Reports  The importance of monthly reports is that they should provide an effective and efficient means of communicating results. Monthly reports should be developed by both we as well as the Sales Manager and by our individual Representatives.  Reports should be consistent in their format since they are going to be used as communication tools to a number of people in a variety of departments.  Reports should be short, concise and to the point detailing performance against objectives, primary accomplishments and items of primary interest.  Reports should be detailed and heavily quantifiable reporting both objectives and results.  Reports should be proactive rather than reactive and should avoid defining history "for the record".  Reports must be regarded as a useful tool and not "busy work"; therefore, they should be equally easy-to-complete and easy-to-read.  We can provide them with examples of a planning and monitoring format that have been used during the past year and proven to be a very effective tool among a large sales force.  They are typically the monthly report formats that are used by US Regional Directors.  These particular formats resulted from the Regional Directors working together to define a reporting and monitoring tool that would be useful to them as managers and useful as a communication vehicle for information given to other departments. REPORT AND MONITOR
  • 48. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 48 monthly sales report/forecast (template) Sales dept/tea m …………. Month ………… This basic sales report/forecast tool is for a small or new businesses which do not yet have a computerized full management information system, which would normally integrate sales reporting with other business processes. Month cumulative (year to date) sales for month actual Plan variance % actua l plan variance % volumes/quantity/number number of orders average order value next month forecast f'cast Plan variance % f'cast plan variance % volumes/quantity/number number of orders average order value quarter forecast f'cast Plan variance % f'cast plan variance % volumes/quantity/number number of orders average order value year forecast f'cast Plan variance % f'cast plan variance % volumes/quantity/number number of orders average order value summary/forecast of sales performance and activities comments on internal services affecting sales and customers (e.g., order processing, customer services, stock, distribution and deliveries/installations, service support, invoicing, major/national contracts, new product development, recruitment and training, etc)
  • 49. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 49 competitor activity market comments (trends, developments, SWOT factors of note, i.e., strengths, weaknesses, opportunities, threats) Report compiled by ……………...………..….. Date ……………….. Leading and Lagging Indicators  It is recommend that we need to monitor both the "Leading" and the "Lagging" Indicators on a daily, weekly and monthly basis in order to track and consistently forecast the performance of our brand. By tracking these results in this manner, we keep our self fully knowledgeable of what is happening in the field and ensure that we and our brand will not be surprised.  Provided below are examples of indicators that we should consider monitoring:  We recommend that we begin this monitoring system formally, but use only a limited number of indicators to begin in order to assure that the process of data collection and reporting actually takes place consistently. Nothing would be more confusing to our management efforts than to begin this tracking process and then abandon because it became too difficult to administer. Leading Indicators to Monitor Daily Sales Flash of ex-factory (shipments) sales Wholesaler inventory levels New end user referrals Sales rep reports on new business Sales rep call activity reports Red Alerts: Competitive activity, reimbursement changes Red Alerts: Flag specific customer sales which drop >10% Field requests for marketing materials
  • 50. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 50 Lagging Indicators to Monitor Wholesaler outflow data Market demand data Reimbursement (Medicaid-US) claims data Pharmacy stocking reports IMS data Tier movement data Primary market research Define our Annual Planning Cycle  To define and outline the components of the annual planning cycle: The purpose of the following table is for we to plan out the primary planning activities for we as Manager and for our Representatives over the period of eighteen months. Planning Cycle Required Input J F M A M J J A S O N D J F M A M J J Input to Marketing Plan Create First rough draft of National Sales Plan Submit Budgets Plan Approvals Complete final National Sales Plan Complete all Regional and territory Plans
  • 51. BRAND PLAN FOR 2010 – GLYCOMET (US VITAMIN) PRESENTATION TEXT BY MITESH SHAH STEVENS BUSINESS SCHOOL 51 Complete Target Account Plans Sales Meetings National Meetings Regional Meetings Territory Meetings